PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

The International Liver Congress 2018

11-15 April 2018 Paris

N. Poster

Poster title

Applicant name

Status


LBP-001	Long-term efficacy and safety of WTX101 in Wilson disease: Data from an ongoing extension of a phase 2 study (WTX101-201)	Karl Heinz Weiss	Received

THU-001	Internalization of canalicular transporters in estradiol 17ß-D-glucuronide-induced cholestasis involves shift from "raft" to "non-raft" membrane domains and clathrin-mediated endocytosis	Gisel S. Miszczuk	Received

SAT-001	miR-21 contributes to the onset and progression of liver disease through the deregulation of small intestine permeability	André A. Santos	Received

FRI-001	A six month follow-up study to determine the clinical utility and patient acceptability of fibroelastography in detection and treatment of alcohol-related liver disease	Lynn Owens	Received

THU-002	Different micro-environtmental factors induce proliferation, epithelial-mesenchymal transition (EMT) and senescence of primary cultures of human biliary tree stem/progenitor cells (hBTSCs), recapitulating the pathological features typical of human cholang	Daniele Costantini	Received

SAT-002	Depletion of Paneth cells is associated with decreased portal hypertension and angiogenesis after partial portal vein ligation in mice.	Mohsin Hassan	Received

FRI-002	Pilot study: evaluation of the role of the coordinating nurse in the management of patients with hepatocellular carcinoma and treated with chemoembolization	julie devictor	Received

THU-003	Transcriptional repressors Zeb1 and Zeb2 regulate collagen production in drug-induced hepatic stellate cell activation in mice.	Inge Mannaerts	Received

SAT-003	A functional metagenomics investigation of cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy	Vincenza Di Gregorio	Received

FRI-003	Patient education results in better sustained virological response to anti-viral therapy in a high number of patients with chronic hepatitis C than conventional care	François Habersetzer	Received

THU-004	Dechipering the role of Axin2/Lgr5+ pericentral hepatocytes	Lara Planas-Paz	Received

FRI-004	Reliability and Validity Study of the Turkish Version of the Chronic Liver Disease Questionnaire	Ferya Celik	Received

LBP-004	Long term outcomes of treatment with Trientine in Wilson Disease: Final results from a multicentre study in patients withdrawn from d-Penicillamine therapy	Karl Heinz Weiss	Received

SAT-005	Iron reduction by venesection alters the gut microbiome in Haemochromatosis patients	John Ryan	Received

FRI-005	Using healthcare professionals views to update and improve the Royal College of Nursing (RCN) Caring for people with liver disease: a competence framework to deliver quality person centred care	Lynda Greenslade	Received

THU-005	A combined laser microdissection and proteomic analysis method for identification of liver tumors signatures	Anne-Aurélie RAYMOND	Received

LBP-005	Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial)	Vishal Patel	Received

LBP-006	PBI-4050, a potential anti-fibrotic drug, improves liver fibrosis in Alström Syndrome, an ultra-rare disease.	Shanat Baig	Received

FRI-006	Hepatitis C treatment in prisons through a nurse-led program with telemedicine	Annika Olsson	Received

THU-006	Identificiation of compounds targeting CD133-positive hepatogellular carcinoma while minimizing the damage on hepatocytes by phenotypic high-content screening	Yeonhwa Song	Received

THU-007	Negative allosteric modulators of metabotropic glutamate receptor subtype 5 protect against hepatic ischemia/reperfusion injury	Clarissa Berardo	Received

SAT-007	Does the gut play a pivotal role in the protective effect of coffee on liver damage?	Antonella Rossi	Received

FRI-008	Is the Presence of Fat and Fibrosis a Higher Mortality Risk Factor Versus Cardiovascular Disease?	Daniel Zaldumbide	Received

SAT-008	Intestinal microbiota significantly alters hepatic expression of energy metabolism genes in mice with acute cholestasis	Sheida Moghadamrad	Received

SAT-009	Fecal microbiota profiles as a diagnostic biomarkers in cirrhosis and hepatocellular carcinoma and the impact of life style and nutrition	Michal Safran	Received

FRI-009	Nurse-led Clinic for Liver Cirrhotic Patients: Effects on Health Related Quality of Life	Maria Hjorth	Received

LBP-010	High Efficacy and Safety of Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, non severe fibrosis HCV GT1b-Infected Patients : Interim Results of the STREAGER Study	Armand Abergel	Received

THU-010	Demethylation increases the expression of type 3 inositol 1,4,5-trisphosphate receptor in hepatocytes	Rodrigo Machado Florentino	Received

SAT-010	Gut microbes mediate liver fibrosis in chimeric mice with human hepatocytes persistently infected with hepatitis B virus	Masaya Sugiyama	Received

LBP-011	A pilot study of empagliflozin for the treatment of non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus	Wah-Kheong Chan	Received

THU-011	Correction of ATP7B Restores Its Sub-Cellular Localisation in Hepatocytes from Wilson s Disease Induced Pluripotent Stem Cells	Jiayin Yang	Received

THU-012	Alternative splicing regulation during the course of liver disease	Hualin Wang	Received

SAT-013	The Impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients	Freya Wellhöner	Received

THU-013	Improving the efficacy of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator	Charlotte Lee	Received

SAT-014	Paradoxically functioning onco-miR-155 and the tumor suppressor miR-194 consensus on PD-L1 immune checkpoint upregulation via MALAT-1 and XIST in hepatocellular carcinoma	Sara Atwa	Received

SAT-015	Circulating NK cells in cirrhosis are hypofunctional, with an expanded inhibitory liver-homing CD56dimCD16+/- NK cell population	Naveenta Kumar	Received

THU-015	hASCs-derived exosomes rescuing rats with acute liver failure by releasing IncRNA H19	yinpeng jin	Received

FRI-016	Outcomes of liver transplantation in patients with non-alcoholic steatohepatitis: high recurrence rate in ultrasound and transientelastography	Ahad Eshraghian	Received

THU-016	A novel Akt activatorSC79 prevents lethal hepatic failure induced by Fas-mediated apoptosis of hepatocytes	Wannan Chen	Received

SAT-017	M2 macrophage specfifc gene silencing in the liver using third generations mannose coated, siRNA-loaded nanohydrogel particles	Leonard KAPS	Received

LBP-017	Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma	Abderrahim OUSSALAH	Received

THU-017	New insights in Transforming Growth Factor Beta signalling pathway on tumor suppression and metastatic potential in primary liver cancer	Sharon Pereira	Received

SAT-018	The pathogenic role of Stat2 in inflammation is independent of canonical interferon signaling and is mediated by TNFa.	William Alazawi	Received

THU-018	Amiodarone-induced adipose tissue endoplasmic reticulum stress and lipolysis may contribute to hepatic lipid accumulation	Inbal Houri	Received

FRI-018	Alcoholic Liver Disease Surpasses Hepatitis C Virus in 2016 to Become the Leading Indication for Liver Transplantation among Adults Without Hepatocellular Carcinoma in the United States	Jennifer Wang	Received

LBP-019	13C-Methacetin Breath Test is a Highly Accurate Non-Invasive Point of Care test for Detecting CSPH in patients with NASH	Jaume Bosch	Received

SAT-019	AXL-expressing monocytes indicate immuneparesis and disease severity in patients with cirrhosis	Robert Brenig	Received

FRI-019	Among Adults with Hepatocellular Carcinoma Awaiting Liver Transplantation, Asians, Hispanics, and Patients with Nonalcoholic Steatohepatitis Have Disproportionately Lower Likelihood of Receiving Liver Transplantation	Jennifer Wang	Received

THU-019	Effectof melatonin on the circadian clock pathway in liver fibrosis and progressionto hepatocarcinoma	Bárbara González Fernández	Received

FRI-020	Risk factors for dropout from the liver transplant waiting list under locoregional treatment	Han Ah Lee	Received

SAT-021	Secreted ectodomain of SIGLEC-9 and MCP-1 ameliorate acute liver failure in rats by altering bone marrow macrophage polarity	Takanori Ito	Received

LBP-021	The percentage of patients with HCV infection in need of a liver transplant is rapidly declining while their survival after transplantation is improving: A study based on European Liver Transplant Registry.	Giovanni Perricone	Received

FRI-021	Outcome of liver grafts procured from hepatitis C-positive donors in the era of direct-acting antiviral drugs: a preliminary single centre experience	Silvia Martini	Received

LBP-022	Mas-related G-protein coupled receptor type D (MrgD) antagonism produces splanchnic vasculature-specific effects, leading to a large reduction in portal pressure in cirrhotic animals	Lakmie Gunarathne	Received

SAT-022	Elevated programmed death ligand 2 (PDL2) in macrophages of BALB/c mice model of liver fibrosis associated with decreased CD80 and IL12 expressions	Johnny Amer	Received

THU-022	Investigating the effect of adrenomedullin on hepatic NF-kB activation by 2D and 3D hepatic cell cultures	Krista Rombouts	Received

FRI-022	Preemptive direct-acting antiviral therapy in naive or NS5A-relapser liver transplant recipients: a single centre experience	Silvia Martini	Received

LBP-023	HCV treatment with DAA in patients listed for liver transplant does not result in an increased risk of HCC recurrence post-liver transplant	Chiara Mazzarelli	Received

FRI-023	Donor-specific anti-HLA antibodies are not associated with non-anastomotic biliary strictures, but both are independent risk factors for graft loss after liver transplantation	Bart van Hoek	Received

LBP-024	Increased risk of liver cancer in cirrhotic patients associated to direct acting antivirals	Maria Reig	Received

SAT-024	Ethanol dampens IL-37 expression in liver tissue	Felix Grabherr	Received

THU-025	Involvement of sphingosine-1P receptor 2 (S1PR2) in taurolithocholate-induced impairment of multidrug resistence-associated protein 2 (Mrp2) in rat	Romina Andermatten	Received

SAT-025	Serum CXCL14 chemokine as a biomarker during murine acute and chronic hepatitis	Christelle Devisme	Received

THU-026	The analysis of delta40p53, one of p53 splicing isoforms, in hepatocellular carcinoma cells.	Haruhisa Nakao	Received

LBP-026	A structurally engineered fatty acid, icosabutate, displays optimised absorption, distribution and metabolism properties for targeting hepatic inflammation and normalises elevated liver enzymes in dyslipidemic patients	David A. Fraser	Received

SAT-026	Autophagy-related liver enzymes in chronic liver disease	Demetrious Samonakis	Received

LBP-027	Rifaximin reduces the incidence of sepsis and all cause admissions whilst on the liver transplant waiting list	Debbie Shawcross	Received

THU-027	CCNT1 mediates mTor inhibitor related antiviral effects in HCV genotype 2a	Alexandra Frey	Received

FRI-027	Incidence of waitlist removal and transplantation rates are similar in NASH, cryptogenic and autoimmune hepatitis cirrhosis	Paul J. Thuluvath	Received

SAT-028	Clinical presentation, natural history and treatment of hepatic sarcoidosis: a case-series of 39 patients with histologically proven hepatic sarcoidosis	Malte Wehmeyer	Received

THU-028	Cerium oxide nanoparticles protect against oxidant mediated injury and recover kinase activity of multiple pathways in human-derived hepatocellular carcinoma cells	Meritxell Perramon Corominas	Received

FRI-028	Liver transplant waitlist mortality, transplantation rates and post-liver transplant outcomes in Hispanics	Paul J. Thuluvath	Received

THU-029	Interaction between hepatic sinusoidalendothelial cells and monocytes modulates IL33 driven Th2 dependent liver fibrogenesis	Johanna Reissing	Received

SAT-029	Upregulation of miR-34c driven by JNK and FOXO3 in livers expressing mutant Z alpha1-antitrypsin	Pasquale Piccolo	Received

LBP-029	Viral integration profiles in the plasma cell-free DNA from patients with HBV infection well represent tumor clone compositions during HCC development	Dake Zhang	Received

FRI-029	Pretransplant Karnofsky Performance Status is an independent predictor of post-liver transplant survival	Paul J. Thuluvath	Received

LBP-030	8 weeks of ledipasvir-sofosbuvir for non-cirrhotic patients with HCV genotype 4: A single-arm multicenter phase 3b study (HepNed-001)	Anne Boerekamps	Received

THU-031	Hypoxia strongly modulates hepcidin mRNA expression via macrophage-hepatocyte crosstalk	Ines Silva	Received

SAT-031	Refinement of diagnostic criteria and frequency estimation of LPAC syndrome: a French multicenter study	Dong Catherine	Received

FRI-031	The Survival Benefit of Hepatic Resection in Advanced Cases for Intrahepatic Cholangiocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis	Mohamed Moustafa	Received

THU-032	Hypoxia enhances H2O2-mediated upreguation of hepcidin: potential role of oxidases in iron regulation	Ines Silva	Received

FRI-032	A nomogram with sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant patients: a competing risk analysis in a national cohort	Jeroen van Vugt	Received

SAT-032	Role of alpha-1 antitrypsin genotypes in the progression of adult liver disease	Vítor Pereira	Received

THU-033	Reduced PI3K pathway in NK cells of F4-NAFLD patients inhibited mTOR expressions and was correlated with their impaired function	Johnny Amer	Received

SAT-033	Genetic ablation of CHOP decreases hepatic accumulation of mutant Z alpha1-antitrypsin	Sergio Attanasio	Received

FRI-033	Tacrolimus cumulative exposure after liver transplantation is associated with a progressive derangement of renal function despite routine dose adjustments	Manuel Rodríguez-Perálvarez	Received

SAT-034	Etiology of splanchnic vein thrombosis in 812 chinese patients from a single center	Guohong Han	Received

SAT-035	Step-wise strategy for Chinese Budd-Chiari syndrome patients: long-term outcome of a large scaleprospective observational cohort	Guohong Han	Received

FRI-035	A beneficial weekend effect? Weekend liver transplantation isassociated with reduced graft and transplant failure	Neil Halliday	Received

THU-035	Metabolic rewiring and de novo lipogenesis induced by Glucokinase expression in hepatocarcinoma cell line	Vincent Lotteau	Received

SAT-036	Hepatic outcomes from childhood intestinal failure: a meta-analysis of 8223 patients	Aureliane Pierret	Received

FRI-036	Long-term Post-transplant Liver Biopsies of Children: Central Perivenulitis is Associated with Circulating Donor-specific Antibodies and Tissue C4d Deposition	Lara Neves Souza	Received

THU-036	Role ofseptin 9 in interferon gsignalling and the development of cholangiocarcinoma	Daniel Zaldumbide	Received

THU-037	Molecular and Histological Characterization of the Pathological Events in a Model of Cirrhosis and Hepatocarcinoma	María Paulette Castro-Gil	Received

FRI-037	DAA therapy improves early post-liver transplant survival and induces significant changes in wait-list composition	Gonzalo Crespo	Received

THU-038	The emerging realm of morphogens in the adult liver of mice and human - a deep insight into distribution, interaction and regulation	Erik Schröder	Received

SAT-038	Comparison between Room-Temperature Susceptometry and MRI with respect to the cell-specific detection of liver iron	Johannes Mueller	Received

FRI-038	Long-term subclinical inflammatory lessions in liver transplant recipients	Maria-Carlota Londoño	Received

SAT-039	Alpha1-antitrypsin augmentation therapy is associated with an improvement in liver-related parameters in patientes with severe alpha1-antitrypsin-deficiency	Carolin Victoria Heimes	Received

THU-039	Direct and indirect hepatoprotective mechanism of CBLB502 a TLR5 agonist	Nicolas Melin	Received

FRI-039	Utility of FDG-PET/CT in pre-transplantation workup of the potential liver recipient with hepatocellular carcinoma	Sang young Yi	Received

FRI-040	Long-term outcome of donor biliary complications following living donor liver transplantation	Hyun Young Woo	Received

SAT-040	Impact of acute hepatic porphyrias on quality of life and work loss: an analysis of EXPLORE natural history study	Sonalee Agarwal	Received

THU-040	Towards understanding the mechanisms of chlorpromazine- induced hepatic toxicity using a human HepaRG- based model.	Joanna Brzeszczynska	Received

SAT-041	Trends in healthcare utilization in the United States and Europe associated with patient with acute hepatic porphyria with recurrent attacks in EXPLORE: a prospective, multinational natural history study of patients with acute hepatic porphyria	Sonalee Agarwal	Received

THU-041	Uncoveringthe liver Notch code using high-throughput reporter imaging on micropatterns.	Jan Mašek	Received

FRI-041	Impact of surgical margin according to AFP ratebefore hepatectomy for hepatocellular carcinoma	Daniel Zaldumbide	Received

SAT-042	PREVALENCE AND PREDICTIVE FACTORS OF HEPATIC NODULES IN PATIENTS WITH FONTAN SURGERY: THE VALDIG FONLIVER STUDY	Enrique Rodríguez-Santiago	Received

FRI-042	Upper limb lean mass by Dual Energy Xray Absorptiometry is associated with increased mortality in men with advanced cirrhosis	Marie Sinclair	Received

SAT-043	The effect of re-exposure to somatostatin analogues in patients with polycystic liver disease	René van Aerts	Received

FRI-043	MELD dynamics predicts waitlist outcomes in patients awaiting liver transplantation	Bo Hyun Kim	Received

SAT-044	The PR interval in the fetal electrocardiogram is significantly prolonged in severe Intrahepatic Cholestasis of Pregnancy and potentially normalised by UDCA therapy	Tharni Vasavan	Received

SAT-045	DIFFERENTIALDIAGNOSTICS OF CONGENITAL CHOLESTATIC DISEASES IN CHILDREN OF EARLY AGE	Galina Volynets	Received

FRI-045	FILAMIN A EXPRESSION PREDICTS EARLY RECURRENCE OF HEPATOCELLULAR CARCINOMA	Ana Lleo	Received

SAT-046	quantitative and qualitative lymphocyte alterations in patients with autoimmune hepatitis: what is the clinical relevance?	Amédée Renand	Received

THU-047	Interim evaluation and projected impact of the hepatitis C virus elimination program in Georgia	Josephine Walker	Received

SAT-047	High caloric nutrition promotes hepatocellular damage and steatohepatitis in Wilson disease rats via amplified mitochondrial damage.	Claudia Einer	Received

FRI-047	Multi-frequency bioelectrical impedance output correlates to liver disease severity, nutritional status and functional capacity	Jane Foo	Received

SAT-048	The natural course of FIC1 deficiency and BSEP deficiency: initial results from the NAPPED-consortium (NAtural course and Prognosis of PFIC and Effect of biliary Diversion).	Daan van Wessel	Received

FRI-048	Pregnancy Outcomes and Reproductive Health After Liver Transplantation	Christina Lindenmeyer	Received

THU-048	Protective effect of cannabis and coffee consumption on HCV-related mortality in French HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort)	Maria Patrizia Carrieri	Received

SAT-049	Mild iron overload in homozygous carriers of the alpha1-antitrypsin PiZ variant is not a major driver of liver fibrogenesis	Nurdan Guldiken	Received

FRI-049	Is a telehealth-to-home group lifestyle intervention a feasible and safe option for specialist liver clinics?	Ingrid Hickman	Received

THU-049	Treatment of Hepatitis C in dedicated homeless GP practice by a multidisciplinary team	Katherine Davidson	Received

THU-050	Comorbid disease burden in patients with primary liver pathologies- data from a Comprehensive Analysis of Serial Transient Elastography and other Liver disease Evaluations at the Toronto Liver Centre (CASTLE-TLC)	Kerstina Boctor	Received

SAT-050	Compound library screening for the identification of a new treatment for polycystic liver disease	Liyanne van de Laarschot	Received

FRI-050	Pre-Liver Transplant Visceral Adipose Tissue Predicts the Early Development of Metabolic Syndrome Post Transplant.	Aidan Woodward	Received

THU-051	Patient monitoring of changes in the European policy response to viral hepatitis C treatment: Hep-CORE findings from 2016 to 2017	Jeffrey Lazarus	Received

FRI-051	Follow-up of non-HLA and anti-HLA antibodies: importance in graft failure after liver transplantation	Speranta Iacob	Received

THU-052	Heterogeneity in hepatitis C virus treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access	Nick Scott	Received

SAT-052	Transcatheter recanalization with angioplasty and/or stenting: a novel, minimally-invasive treatment option for children with chronic portal vein thrombosis with cavernous transformation	Henri Justino	Received

FRI-052	CXCL9 and CXCL10 gene polymorphisms are associated with earlier onset of acute cellular rejection after liver transplantation	Ana Ostojic	Received

FRI-053	Post-transplantation Outcomes in Cirrhosis secondary to Granulomatous Liver Diseases	Avesh Thuluvath	Received

SAT-053	Clinical response after laparoscopic fenestration of large simple hepatic cysts: a systematic review	L.H.P. Bernts	Received

THU-054	The time trend of proportion and mortality rate of admissions associated with acute respiratory illness in cirrhotic patients with diverse ethnicity and socioeconomic status: an analysis on the U.S. National Inpatient Sample	Donghak Jeong	Received

FRI-055	99mTechnetium-MebrofeninHepatobiliary Scintigraphy predicts portal hypertension in Child-Pugh Acirrhosis	Thiery Chapelle	Received

THU-055	The cost-effectiveness of needle and syringe provision in preventing transmission of Hepatitis C virus in people who inject drugs	Zoe Ward	Received

FRI-056	Chronic Rejection in Children: Risk factors, Diagnosis and Outcome	Tamir Miloh	Received

THU-057	Quantifying the Impact of Achieving the World Health Organization (WHO) Global Health Sector Strategy (GHSS) Goals for Hepatitis C in the EURO Region	Sarah Robbins	Received

THU-058	Quantifying the Impact of Achieving the World Health Organization (WHO) Global Health Sector Strategy (GHSS) Goals for Hepatitis C in the African Region	Sarah Robbins	Received

SAT-058	The Galactose Elimination Capacity test may monitor treatment response and disease progression in patients with Wilson Disease	Thomas Damgaard Sandahl	Received

FRI-058	Stabilization of acute-on-chronic liver failure patients before liver transplantation predicts post-transplant survival.	Peter Huebener	Received

THU-059	Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the "underwater portion of the iceberg" matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries?	Sarah Robbins`	Received

SAT-059	The global prevalence of lysosomal acid lipase deficiency estimated by meta-analysis of pathogenic mutations and functional variants from next-generation sequencing data	Anna Carter	Received

FRI-059	High mortality after liver transplantation for cirrhotic patients with previous spontaneous peritonitis occurring within one year prior to transplantation	Mayada Elnegouly	Received

SAT-061	Liver disease in a cohort of patients with Gaucher disease from Southern Brazil: a cross-sectional study.	Rodrigo Starosta	Received

THU-061	Improved Health Outcomes fromHepatitis C Treatment Scale-Up in Spain´s Prisons: A Cost-Effectiveness Study	Jagpreet Chhatwal	Received

FRI-061	Donor liver small droplet macrovesicular steatosis is associated with reduced graft survival after liver transplantation	Flaminia Ferri	Received

THU-062	Poor awareness of liver disease shortly before cirrhosis death: findings from a large community cohort in the UK	Hamish innes	Received

SAT-062	Characteristics associated with non-response to ursodeoxycholic acid in primary biliary cholangitis	Teresa Dias	Received

FRI-062	Liver transplantation in HIV patients: a descriptive cohort study	Sara Castelo Branco	Received

THU-063	Eradicate Hepatitis C: a pilot of treatment as prevention in active drug users	Jasmine Schulkind	Received

SAT-063	Evaluation of the New criteria in the diagnosis of cystic fibrosis liver disease	Ilianna Mani	Received

THU-064	HIV co-infection is associated with increased liver complications and reduced mental health among patients with chronic hepatitis B	Mei Lu	Received

SAT-065	Transient elastography as a screening method for chronic liver disease in apparently healthy population. Results from de ETHON cohort.	Elba Llop	Received

THU-065	Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake	Jisoo Amy Kwon	Received

THU-066	HEPCARE EUROPE: HEPCHECK; REACHING VULNERABLE POPULATIONS	Jack Lambert	Received

FRI-066	Inducible ablation of TGFß receptor type 2 limited to hepatic stellate cells potently inhibits liver fibrosis and attenuates inflamation	Olena Molokanova	Received

SAT-066	Prognostic Value of 2D-Shear Wave Elastography(2D-SWE) for staging cirrhosis in chronic liver diseases (CLD) in two severity classes according to liver-related complications	Priscila Pollo-Flores	Received

THU-067	Achieving World Health Organization targets for hepatitis B by 2030: Results from 17 WHO AFRO Countries	Helen Nde	Received

SAT-067	Reliability criteria for liver stiffness measurement with ARFI	Jerome Boursier	Received

FRI-067	Caspase-8 is a gender-specific modulator of chronic cholestatic liver disease in female Mdr2 knockout mice.	Julia Jung	Received

SAT-068	The ProC3 marker of type III collagen formation accurately reflects hepatic inflammation and fibrosis stage in asymptomatic alcoholic liver disease patients	Maja Thiele	Received

THU-068	Achieving World Health Organization targets for hepatitis B in infants and 5-year olds by 2030: Results from 17 WHO AFRO countries	Helen Nde	Received

FRI-068	Novel pro-fibrotic properties of macrophage migration inhibitory factor in non-alcoholic steatohepatitis is associated with a shift in natural killer T cell populations	Daniel Heinrichs	Received

FRI-069	High density lipoproteins production induced by selective intestinal LXR activation protects against the progression of liver injury by shifting M1 to M2 Kupffer cell phenotype.	Irene Pierantonelli	Received

THU-069	Impact of the hepatitis B vaccine birth-dose on perinatal incidence between 2017-2050: Results from 17 WHO AFRO Countries	Helen Nde	Received

SAT-070	Liver stiffness measurement predicts short-term liver related-morbidity of allogeneic hematopoietic stem cell transplantation	Thomas Karlas	Received

FRI-070	Increased expression of pregnancy-associated plasma protein-A in activated hepatic stellate cells is a potential therapeutic target and serum marker of hepatic fibrosis	Freese Kim	Received

THU-071	The ENABLE projects: Consistent high prevalence of undiagnosed active blood borne virus infection [HBV, HCV, HIV] across four urban emergency departments in England. - Data for action?	Mark Hopkins	Received

FRI-071	Oncostatin M regulates the role of macrophage during progression and resolution of hepatic fibrosis	Michitaka Matsuda	Received

SAT-071	Liver stiffness measurement by 2D SWE from General Electric is similar with Transient Elastography in clinical significant portal hypertension diagnosis	Rusu Corina	Received

SAT-072	Controlled Attenuation Parameter reflects intrahepatic fat content in patients with compensated advanced chronic liver disease	Rosangela Piccinni	Received

THU-072	Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population	Jelle Koopsen	Received

FRI-072	Selective NDRP1 E3 ubiquitin ligase overexpression in inflammatory macrophages using functionalized carbon nanoparticles promotes fibrosis regression in cirrhotic mice	Pedro Melgar-Lesmes	Received

FRI-073	Platelet c-type lectin-like receptor reduces cholestatic liver injury in mice	suguru maruyama	Received

FRI-074	AXL increase in NASH patients and anti-fibrotic efficacy of AXL inhibition in experimental NASH	Anna Tutusaus	Received

THU-074	Scale-up of the national HCV screening and treatment program in Indonesia: data from Jakarta, West Java and Central Java	Atiek Anartati	Received

SAT-074	Usefulness of liver stiffness measurement by transient elastography (TE) for predicting complications in patients with alcoholic liver disease	Ana Gomez	Received

SAT-075	Evaluation of Multiparametric MRI in comparison with MR Elastography in patients evaluated for chronic liver disease	Stephen Bravo	Received

THU-075	Hepatitis C screening within the National Elimination Program in the country of Georgia	Ana Aslanikashvili	Received

FRI-075	Platelet-derived growth factor receptor alpha deprived hepatocytes attenuate thioacetamide induced liver fibrosis in mice	JUNG IL LEE	Received

FRI-076	PLATELET DEACTIVATION ATTENUATES CCL4 INDUCED LIVER FIBROSIS PROGRESSION IN MICE.	Adil Bhat	Received

SAT-076	Glomerular filtration rate evaluation in patients with cirrhosis, which equation shall be used in clinical daily practice?	Sofia Monteiro	Received

THU-076	Inferring the migration routes of hepatitis C virus subtype 1a lineages identifies a need for pan-European prevention strategies	Lize Cuypers	Received

THU-077	Outcomes of hepatitis C testing, linkage to care, and treatment in a community based program in high versus low prevalence sites	Lora Magaldi	Received

SAT-077	Predictions from a very hard liver: the role of liver stiffness in alcoholic hepatitis	Fischer Petra	Received

SAT-078	Soluble serum vascular adhesion protein (sVAP)-1: a new biomarker in primary sclerosing cholangitis?	Francesca Saffioti	Received

FRI-078	Non-invasive Phenotyping of Hepatic Fibrosis using Unsupervised machine Learning	Yuta Nakano	Received

THU-078	Testing and linkage to care outcomes in baby boomers versus young adults tested in the community and linked to care at a Federally Qualified Health Center in the US	Lora Magaldi	Received

THU-079	The impact of EMR modification and a multi-disciplinary care team on the hepatitis C care cascade of a US Federally Qualified Health Center	Lora Magaldi	Received

SAT-079	Comparison of twelve noninvasive liver reserve models in HCC patients undergoing resection	Shu Yein Ho	Received

THU-080	Identifying patients with cirrhosis at high risk of readmission: a population-based data-linkage Australian study	Patricia Valery	Received

SAT-080	Enhanced Liver Fibrosis (ELF) Test predicts liver-related outcomes in postmenopausal women with risk factors in the community	Paul Trembling	Received

FRI-080	Human amnion epithelial cells reduce liver fibrosis via effects on macrophages phenotype and liver progenitor cells in murine liver injury	majid alhomrani	Received

SAT-081	Correlation between controlled attenuationparameter assessed with Fibroscan and steatosis percent objectively quantifiedfrom the entire liver biopsy specimen using a computer analysis tool. Preliminary results.	Monica Lupsor-Platon	Received

THU-081	The role of a template-based assessment letter in the continuing education of general practitioners: a qualitative exploration of NAFLD educatioin	Patricia Valery	Received

THU-082	THE FIRST LARGE SCALE REGISTRY FOR NON ALCOHOLIC FATTY LIVER DISEASE IN ISRAEL	Inbal Goldshtein	Received

SAT-082	Performance of shear-wave elastography to detect high-risk esophageal varices in cirrhosis is improved by spleen stiffness estimation	Seong Hee Kang	Received

FRI-082	Zoledronic Acid suppresses tumour associated macrophages andmyeloid derived suppressor cells in murine HCC	Misbah Aslam	Received

FRI-083	Rapamycin and Zoledronic acid exert a potent antifibrotic effect in murine biliary fibrosis	Misbah Aslam	Received

SAT-083	Non-invasive estimation of hepatic fibrosis and steatosis: comparison of 2D shear-wave elastography and acoustic structure quantification with transient elastography and controlled attenuation parameter	Valentin Blank	Received

SAT-084	CT-driven Model for End-Stage Liver Disease: Comparison of Survival Prediction with MELD score	Ji Eun Lee	Received

THU-084	Is macro-elimination of HCV infection the right approach for Canada?	Julie Holeksa	Received

FRI-084	EDP-305, a highly selective and potent farnesoid X receptor agonist, favorably regulates the expression of key fibrogenic genes in vitro and in vivo	Lijuan Jiang	Received

SAT-085	Non invasive assessment of liver fibrosis by three different Shear Wave Techniques: Head-to-Head Performance	Sebastiana Atzori	Received

THU-085	Low rates of prenatal testing for hepatitis B and C infections in Ontario, Canada	Mia Biondi	Received

THU-086	Scale up of hepatitis C virus treatment in the era of all-oral direct-acting antivirals (DAAs): a 9-year Greek cohort study.	Vasilios Papastergiou	Received

FRI-086	Possible liver regeneration and anti-fibrogenic effect of NOTCH1 selective inhibitor in the diseased liver model	Mitsuteru Kitade	Received

THU-087	Design and cost effectiveness of a hepatitis C virus elimination strategy based on an updated epidemiological study (ETHON cohort)	Antonio Cuadrado	Received

SAT-087	Comparison of T2* and Signal Intensity Ratio Methods for MRI Assessment of Hepatic Iron Overload	Christopher Kagay	Received

THU-088	Hepatitis C infection in the Pan American Health Organization Region: The current burden of disease and a road map for achieving the WHO Global Health Sector Strategy Goals	Jonathan Schmelzer	Received

SAT-088	Serum biomarker usein decentralized care sites to overcome liver assessment barriers in patientswith chronic hepatitis C and HIV co-infection	anne Loarec	Received

FRI-088	During the progression of liver fibrosis, myofibroblasts develop endoplasmic reticulum stress that both decreases their proliferation and increases their pro-angiogenic activity	Axelle Cadoret	Received

THU-089	}The current and future disease burden of hepatitis B in the general population and among five year olds in the Eastern Mediterranean Region	Jonathan Schmelzer	Received

SAT-089	Normal liver elasticity values in a healthy population, by age and gender, for two novel elastography systems	Anesa Mulabecirovic	Received

THU-090	THE COVERT C ; PREVALENCE , RISK FACTORS AND MANAGEMENT OF HEPATITIS C IN PSYCHIATRIC IN-PATEINTS	Jeyamani Ramachandran	Received

SAT-090	Detection of Hereditary Haemochromatosis in the clinic and community using standard haematological tests: a comparison with iron studies	Nancy Whalen	Received

FRI-090	Performance of quantitative collagen parameters for assessing longitudinal non-advanced liver fibrosis	Yan WANG	Received

SAT-091	Evolving diagnostic pathways in liver disease: using quantitative magnetic resonance imaging to distinguish parenchymal and biliary disease.	Katherine Arndtz	Received

THU-091	Modelling the impact and efficiency of screening and treatment scale-up for hepatitis C virus in Pakistan: Working towards elimination	Aaron G. Lim	Received

FRI-091	RNA-sequencing analysis of biopsies from chronic liver disease patients identifies gene signatures associated with progressive liver disease	Divya Ramnath	Received

SAT-092	Non invasive diagnostic approach for screening and grading of portal hypertension in patients with advanced liver disease.	Sergii Kozlov	Received

FRI-092	Interference of PTTG1 mRNA dramatically reduces portal hypertension and liver fibrosis in fibrotic rats.	Silvia Carvajal Restoy	Received

THU-092	Characteristics and outcomes of patients with late presentation of hepatitis B among newly-diagnosed hepatocellular carcinoma : A national cohort study 2002-2013	Dong Hyun Sinn	Received

THU-093	Evaluation of the Xpert Fingerstick HCV Viral Load assay	François Lamoury	Received

SAT-093	Circulating micro-ARNs as biomarkers of alcohol liver disease and hepatocellular carcinoma	Charles-Antoine PAPILLON	Received

FRI-093	Direct fibrosis markers kinetic in patients undergoing antiviral treatment with DAA for chronic hepatitis C	Chiara Mazzarelli	Received

THU-094	Sero-prevalence of Hepatitis B surface antigen among 5-7 years old children and their mothers in Cambodia by nationwide multi-stage stratified random sampling strategy	Junko Tanaka	Received

SAT-094	Liver function assessment using magnetic resonance imaging with gadoxetic acid administration	Christina Levick	Received

FRI-094	SWAVE: Steady State Shear Wave Elastography for Fibrosis Evaluation in Liver Disease	Caitlin Schneider	Received

SAT-095	Platelet and spleen volume criteria exclude more oesophageal varices needing treatment than Baveno VI criteria with 100% sensitivity	Christina Levick	Received

THU-096	Khat chewing increases the risk for developing chronic liver disease: a hospital-based case-control study	stian orlien	Received

FRI-096	AGAP2, a new player in TGF-beta signalling	Amaia Navarro-Corcuera	Received

SAT-097	Using Wisteria floribunda agglutinin-positive Mac2-binding protein in combination with the FIB-4 index to predict significant liver fibrosis	Tomi Jun	Received

THU-097	The Global Prevalence of HBsAg by Age in 2016 and the Case for Universal Treatment in Low and Middle Income Countries	Daniel Zaldumbide	Received

FRI-098	Establishment of an ex vivo model of human fibrotic liver slices culture: characterization of intrahepatic immune cells and TH17 cytokines	Daria Kartasheva	Received

SAT-099	Distribution and changes of FIB-4 index in normal health checkup examinees	Shuhei Hige	Received

THU-099	Lowering the upper limit of serum alanine aminotransferase levels may detect significant liver disease in the elderly	Hemda Schmilovitz-Weiss	Received

FRI-099	Endocannabinoid system contributes to activation of neutrophils in mouse chronic liver injury	Liying Li	Received

SAT-100	Which is the chance for type 2 diabetes patients to develop severe liver disease?	Ioan Sporea	Received

FRI-100	Exosomes secreted by the hepatocytes can inhibit and reverse hepatic stellate cells stimulation	Michal Safran	Received

THU-100	Hepatitis C (HCV) patients with HIV co-infection demonstrate unique liver-related complications and health behaviors compared to HCV mono-infected patients	Stuart C Gordon	Received

THU-101	Progress toward hepatitis C virus elimination through provision of care and treatment services, Georgia, 2015-2017	David SERGEENKO	Received

SAT-101	Intelligent Liver Function diagnostic pathway - Relevance of alanine transaminase normal values.	Emma Robinson	Received

THU-102	High prevalence of hepatitis delta virus in specimens from Cameroon	Mary Rodgers	Received

FRI-102	25(OH) D3 alleviate liver NK cytotoxicity in early but not in late fibrosis model of Balb/c mice due to modulations in vitamin D receptor	Johnny Amer	Received

FRI-103	Role of the protein tyrosine kinase Mer (MerTK) in the cross-talk between macrophages and hepatic stellate cells	Mirella Pastore	Received

FRI-104	PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model.	François Sarra-Bournet	Received

THU-104	The first result from the general population hepatitis screening in Mongolia: 38% of 40-65 year olds screened and anti-HCV prevence of 15.6% among 40-65 year olds	Bekhbold Dashtseren	Received

SAT-104	Phenotypic characteristics and improvement of liver stiffness measurement during follow-up in patients with Wilson s disease	Razvan Iacob	Received

SAT-105	IsFood-intake a Confusing Factor For Liver Stiffness Evaluation by2D-SWE in Normal Subjects?	Alina Popescu	Received

THU-105	Diagnosis of hepatitis C virus infection in Spain. On the correct side of the road?	Federico Garcia Garcia	Received

FRI-105	the wrong or "right" effects of HCV on cardiac function in patients with low-mild liver fibrosis: a case-control study	Andrea Dalbeni	Received

SAT-106	Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients	Elton Dajti	Received

THU-106	HepCARE: A tool enabling the identification, assessment and management of viral hepatitis. An integrated approach to the patient journey	Benjamin Anthony	Received

THU-107	A tool to measure the impact of inaction towards elimination of hepatitis C virus: A case study in Germany	Markus CORNBERG	Received

FRI-107	Primary human HSC cell phenotype is differentlyregulated by pro-fibrogenic and pro-inflammatory stimuli in cirrhotic andhealthy human liver 3D ECM scaffolds	Krista Rombouts	Received

THU-108	Linkage to HCV Care and Reincarceration Following Release from New York City Jails	Matthew Akiyama	Received

FRI-108	Integrin avß6-targeted Near-Infrared/Positron Emission Tomography Contrast Agent for Liver Fibrosis Imaging	Yong Ook Kim	Received

THU-109	Impact of elevated coffee intake on the risk of advanced liver fibrosis in HIV-HCV co-infected patients of the French ANRS CO13 HEPAVIH cohort: a sex-based analysis	Issifou YAYA	Received

THU-110	High agreement with HCV RNA in screening and DAA treatment monitoring indicates that cost-effective HCV core Ag test can also be enlisted in the fight to eliminate hepatitis C	Nazibrola Chitadze	Received

THU-111	Elimination of Hepatitis C in two different Swiss Regions - A Model-Based Microelimination Scenario	Urs Rusch	Received

FRI-111	Glycosyltransferase GLT25D2 acts as a negative regulator of autophagy to promote acetaminophen-induced hepatotoxicity	Feng Ren	Received

SAT-111	An effective defatting cocktail to reduce liver graft steatosis before transplantation	Lynda Aoudjehane	Received

FRI-112	Generation of a unique liver progenitor cell gene signature to identify LPCs and LPC activation in chronic liver diseases	Stefaan Verhulst	Received

SAT-112	A merged protocol of hypothermic oxygenated machine perfusion and normothermic machine perfusion optimises the reconditioning of marginal donor livers	Yuri Boteon	Received

THU-112	Role of physician specialties to close gaps in the care cascade of hepatitis C: Evidence from paid claims in the United States from 2010 to 2016	Yuri Sanchez	Received

THU-113	Effectiveness of hepatitis C virus [HCV] screening laws in United States [US]: Evidence from paid claims data from 2010 to 2016	Yuri Sanchez	Received

SAT-113	The effectiveness of a pharmacological intervention for defatting of primary human hepatocytes and its effect on other cell types ofthe liver: a precursor in-vitro study to the defatting of steatotic humanlivers using normothermic machine perfusion	Yuri Boteon	Received

FRI-113	Osteopontin might be a central regulator of inflammation during postoperative liver regeneration in humans	David Pereyra	Received

THU-114	Development of a clinical prediction score for targeted hepatitis C screening in a low-risk HIV cohort in Cambodia	Anja De Weggheleire	Received

FRI-114	Obeticholic acid improves fetal hypercholanaemia during cholestatic gestation	Vanessa Pataia	Received

SAT-115	Establishing a porcine model of small for size syndrome following liver resection	Mohammad Golriz	Received

THU-115	The hepatitis C continuum of care among HIV infected individuals in the Icona study network	Antonella d´Arminio Monforte	Received

FRI-115	In vivo functional genetics for liver regeneration and disease	Viktoriia Iakovleva	Received

THU-116	One-step diagnostic strategy of viremic hepatitis C virus infection from dried-blood spots: feasibility and usefulness in people who inject drugs	Verónica Saludes	Received

SAT-116	Induction of beta-catenin in embryonic stem cell-derived dendritic cells alleviates liver damage in mouse liver inflammatory injury	BIBO KE	Received

FRI-116	Differentiation of human pluripotent stem cells into hepatocytes is more efficient in spheroids than in 2D culture	Messina Antonietta	Received

THU-117	The contribution of injecting drug use to Hepatitis C virus transmission globally, regionally, and at country level: a modelling study	Adam Trickey	Received

SAT-117	Sealant pathology	Omid Ghamar Nejad	Received

FRI-117	Hepatic autophagy potentiates ureagenesis and its enhancement protects against acute and chronic hyperammonemia	Leandro Soria	Received

SAT-118	Preoperative biliary drainage reverses cholestasis-associated inflammatory and fibrotic gene signatures in patients with perihilar cholangiocarcinoma	Rowan van Golen	Received

THU-118	Comparing the prevention gains of different treatment strategies at the global, regional, and country level: a modelling study	Adam Trickey	Received

FRI-119	Liver biopsy derived induced pluripotent stem cells provide unlimited supply for the generation of hepatocyte-like cells.	Diego Calabrese	Received

THU-120	Mass screening for hepatitis B and C in South Upper Egypt: lessons learned from a real life experience	Mahmoud Elzalabany	Received

FRI-120	Mechanisms of action of cortisol in steatotic and non-steatotic livers subjected to partial hepatectomy with vascular occlusion	Esther Bujaldon	Received

THU-121	Track,Trace & Treat: Results from a retrieval strategy to identify lost to follow-up chronic hepatitis C patients	Isabelle Munsterman	Received

FRI-121	Double resin casting micro computed tomography (DUCT) of biliary and vascular system	Simona Hankeova	Received

THU-122	Community interventions and peer support for active case finding and treatment support for underserved populations with hepatitis C in the UK, Ireland, Romania and Spain as part of the HEPCARE programme	julian surey	Received

SAT-122	Distinct functions of phosphorylated and un-phosphorylated STAT1 in hepatocellular carcinoma	Buyun Ma	Received

FRI-122	Human skin-derived precusor cells: a potential source for cellular therapy of the liver	Joery De Kock	Received

THU-123	Virological and clinical characterization of a hepatitis A outbreak in Barcelona involving primarily men who have sex with men	sergio Rodríguez-Tajes	Received

FRI-124	Bile duct organogenesis using ECM micropatterning	Mazari-Arrighi Elsa	Received

SAT-124	Nrf2 pathway plays an important role in the development of hepatocellular carcinoma: the gene expression signature of Nrf2 observed in a rat hepatocarcinogenesis model	Carlos David López	Received

SAT-125	ADAR-mediated A-to-I RNA Editing in Human Hepatocelluar Carcinoma	Guangqi Song	Received

THU-125	Increasing Access to Treatment for Hepatitis C by Vulnerable, High Risk Patients Through Community Pharmacy: the SuperDOT-C Study in Scotland	Andrew Radley	Received

THU-126	Drug utilization in patients with liver cirrhosis in ambulatory care	sander borgsteede	Received

SAT-126	Sulfatase 2 Antagonizes Starvation-Induced Autophagy in Hepatocellular Carcinoma	Paola Romecin	Received

SAT-127	In vivo knockdown of Plk1 using a novel breakable mesoporous silica particle siRNA carrier reduces tumor growth in an orthotopic xenograft mouse model of hepatocellular carcinoma	François H.T. Duong	Received

THU-127	Long-term effectiveness of Sofosbuvir-Based Hepatitis C regimens in Central and West Africa (ANRS 12342)	Maël Baudoin	Received

FRI-127	While Hepatocellular Carcinoma (HCC) Has Become the Leading Indication for Liver Transplantation in the United States, the Probability of Receiving Liver Transplantation Among Adults with HCC Has Rapidly Declined	Jennifer Wang	Received

THU-128	Cost-effectiveness of Sofosbuvir-Based Hepatitis C regimens in Central and West Africa (ANRS 12342)	Sylvie Boyer	Received

SAT-128	CeO2NPs ARE SIMILARLY EFECTIVE AS SORAFENIB IN INCREASING SURVIVAL IN RATS WITH HCC	Guillermo Fernández Varo	Received

FRI-128	Two new blood tests for identifying patients with chronic liver diseases, at high risk of primary liver cancer.	Thierry Poynard	Received

THU-129	HCV screening in the adult general population of a basic health area in the Valencian Region (Spain)	ANTONIO GARCIA HEROLA	Received

SAT-129	Hepatocyte c-Jun N-terminal kinases determine cell fate and carcinogenesis in NEMO-deficient mice	Mohamed Ramadan Mohamed	Received

FRI-129	Contrast-enhanced ultrasound for non-invasive diagnosis of hepatocellular carcinoma: a comparison between CEUS LI-RADS and ESCULAP criteria in a large high-risk cohort of patients	Antonio Saviano	Received

SAT-130	Chemokine receptor CXCR3 modulates polarization of tumor associated macrophages limiting tumor growth and angiogenesis in murine hepatocellular carcinoma	Elisa Fabiana Brandt	Received

THU-130	The nature and impact of stigma in patients with chronic hepatitis B: a systematic literature review	Kristien Bonroy	Received

FRI-130	Tumour progression and recurrence after direct acting antiviral therapy for hepatitis C in patients with previously treated or active hepatocellular carcinoma	Simone Strasser	Received

SAT-131	Hepatocyte-derived Osteopontin drives the development of hepatocellular carcinoma	Romain Desert	Received

THU-131	Cost-effectiveness of scaling up Hepatitis C virus prevention, testing and treatment interventions among people who inject drugs in the US	Hannah Fraser	Received

FRI-131	Identification of keratin 19-positive cancer stem cells associating human hepatocellular carcinoma using 18F-FDGPET and CYFRA 21-1	Takayuki Kawai	Received

SAT-132	AAV2 viral infection in liver and tumor development	Tiziana La Bella	Received

FRI-132	Hepatocellular carcinoma (HCC) after direct-acting antivirals (DAA) does not show differences at diagnosis compared with HCC after IFN-based treatments. Results of a national HCC Registry in Spain	Carlos Rodríguez de Lope	Received

THU-132	HEV positivity in domesticated pigs and a relative risk of HEV zoonosis among occupationally exposed individuals in Vietnam	Xuan Hoan Nghiem	Received

SAT-133	Sorafenib increases the percentage and cytotoxicity of circulating NK cells in hepatocellular carcinoma patients	Guohong Han	Received

FRI-133	Regression of fibrosis stage after treatment in patients with HFE haemochromatosis and severe fibrosis at diagnosis: relevance to hepatocellular carcinoma	edouard Bardou-Jacquet	Received

THU-133	Is HCV elimination among HIV-infected people who inject drugs possible through HCV treatment targeting HIV/HCV coinfection? A modeling analysis for Andalusia, Spain	Britt Skaathun	Received

SAT-134	Rapamycin and Zoledronic Acid strongly inhibit growth of advanced murine hepatocellular carcinoma via activation of innate and adaptive immunity	Muhammad Ashfaq-Khan	Received

THU-134	Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study	Behzad Hajarizadeh	Received

FRI-134	Nonalcoholic Fatty Liver Disease is the Most Common Cause of Hepatocellular Carcinoma (HCC) in Individuals without Cirrhosis: A United States Multicenter Study	Andrew deLemos	Received

FRI-135	Clinical effectiveness of enhanced surveillance in "super-high risk" cirrhotics as evaluated in the ITA.LI.CA. Study Group	Filippo Pelizzaro	Received

THU-135	The French Donor Risk Index for liver transplantation: development, internal and external validation.	Audrey Winter	Received

SAT-136	Insulin receptor isoform A is a new player in the progression of hepatocellular carcinoma	Eva Benabou	Received

THU-136	Looking for the best matching between donor and recipient in liver transplantation: a sequential stratification approach.	Audrey Winter	Received

FRI-136	Patterns of glutamine synthetase expression as marker of beta catenin activation in hepatocellular adenomas	Christine Sempoux	Received

THU-137	One-year injecting frequency trajectories as predictors of hepatitis C acquisition: findings from an observational cohort study of people who inject drugs in Montréal, Canada	Emmanuel Fortier	Received

SAT-137	Defective DNAM-1 mediated cytotoxicity in NK cells infiltrating hepatocellular carcinoma	Barbara Oliviero	Received

FRI-137	Usefulness of newly proposed albumin-bilirubin grade and its modification -Japan nationwide survey	Atsushi Hiraoka	Received

SAT-138	Difference of gene mutational profile among viral- and non-viral HCC with or without prior HBV infection: Results of comprehensive deep sequencing analyses of cancer genes and HBV/AAV integration	Fukiko Kawai-Kitahata	Received

THU-138	Cost-effectiveness of elbasvir/grazoprevir + sofosbuvir for the treatment of chronic HCV genotype 3 infection in Argentina	Emiliano Bissio	Received

FRI-138	Serological diagnosis of early HCC in NASH: A German multicenter study	Jan Best	Received

SAT-139	Therapeutics of cell-specific MAPK modulation in chronic liver disease using (siJNK2) nanodelivery	Marius Woitok	Received

THU-139	Molecular Epidemiology of Hepatitis B and D in the Pacific Islands of Kiribati	Kathy Jackson	Received

FRI-139	Deviations of the immune cell lanscape between healthy liver and hepatocellular carcinoma	Nataliya Rohr-Udilova	Received

SAT-140	Deletion of MyD88 in non-parenchymal cells, but not in parenchymal cells attenuates the progression of hepatocellular carcinoma	Antje Mohs	Received

THU-140	SCREENING AND TREATMENT OF HEPATITIS C VIRUS INFECTION OF ADULT GENERAL POPULATION IN SPAIN IS COST-EFFECTIVE	Maria Buti	Received

SAT-141	Interventional gene targeting of cell cycle regulators identifies Cyclin E1 as a suitable target for attenuating hepatocellular carcinoma progression	Roland Sonntag	Received

FRI-141	Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance	Julien Calderaro	Received

THU-141	Efficacy of a program based on on -site dried blood spot testing for hepatitis C to improve linkage to care and treatment uptake for people who injected drugs	Dalia Morales Arraez	Received

SAT-142	Quantitative comparison of PD-L1 immuno-histochemical assays in hepatocellular carcinoma: the Blueprint-HCC study.	David James Pinato	Received

FRI-142	Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20 year experience from a national programme	Ibrahim Hassan	Received

THU-143	Screening for hepatitis C in Ontario, Canada: Exploring antibody positivity in the federal and provincial correctional systems	Kinsey Beck	Received

SAT-143	Mixed HCC-ICC Liver Cancer Derives From Hepatic Progenitor Cells- a Lineage Tracing Investigation in Mouse Liver Inflammation Models	nofar rosenberg	Received

FRI-143	Prospective evaluation of gadoxetic-acid MR for the non-invasive diagnosis of hepatocellular carcinoma in newly detected nodules <=2 cm in cirrhotic patients	Alejandro FORNER	Received

SAT-144	Circulating exosomal non-coding RNAs as prognostic biomarkers in human hepatocellular carcinoma	Yu Rim Lee	Received

THU-144	Can HCV be eliminated among HIV-infected MSM in Berlin? Modeling a setting with increasing incidence and high treatment rates.	Patrick Ingiliz	Received

FRI-144	Risk of early de-novo hepatocellular carcinoma (HCC) in patients with genotype-1b HCV compensated cirrhosis treated with 3 direct-acting antivirals (DAAs) - a real life, multicenter study	Cristina-Maria Muzica	Received

FRI-145	Incidence of HCC in TIPS bearing cirrhotic patients.	José Manuel Garcia-Ortiz	Received

THU-145	Hepatitis C elimination by 2030 is feasible in Brazil: a mathematical modelling aproach	Maria Cassia Mendes Correa	Received

THU-146	Micro-elemination of hepatitis C among patients with congenital bleeding disorders in Slovenia	Mojca MATICIC	Received

FRI-146	LYMPHOID INFILTRATE PREDICTS PROGNOSIS OF MASS-FORMING INTRAHEPATIC CHOLANGIOCARCINOMA UNDERGOING COMPLETE LIVER RESECTION	Ana Lleo	Received

SAT-147	In-vivo validation of cancer genes using liver organoids	Anna Saborowski	Received

THU-147	Hepatitis E in pigs in Israel: seroprevalence, molecular characterization and potential impact on humans	Orna Mor	Received

SAT-148	Activated platelets contribute to the progression of hepatocellular carcinoma by altering the immune cell environment	Natasa Pavlovic	Received

FRI-148	Gp38+ hepatic progenitor cell-derived large extracellularvesicles in biliary cancers - a novel liquid biopsy marker?	Sabine Urban	Received

SAT-149	Polyploidy and chromosomal instability correlates with proliferative traits and lack of immune-related gene signatures in hepatocellular carcinoma	Laia Bassaganyas	Received

FRI-149	Recommendations for the management of women with suspected hepatocellular adenoma and childbearing potential	Marcia Gaspersz	Received

FRI-150	Preoperative van Willebrand factor is a predictor for early recurrence and overall survival in patients undergoing liver resection for oncological entities	Patrick Starlinger	Received

SAT-150	Tumor-stroma crosstalk enhances Reg3A expressions that drives the progression of hepatocellular carcinoma	Yuri Cho	Received

THU-151	Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib andpravastatin vs best supportive care for the palliative treatment of HCC inCHILD B cirrhotic patients	Jean-Frédéric Blanc	Received

SAT-151	Inhibition of YAP activation induces cell senescence and autophagy while blocking cell proliferation in cholangiocarcinoma (CCA)	Massimiliano Cadamuro	Received

FRI-151	Treatment and prognosis of hepatic epithelioid hemangioendothelioma based on SEER data analysis from 1973 to 2007	Soon Sun Kim	Received

FRI-152	The validity of serum midkine, dickkopf-1 and alpha-L-fucosidase as surrogate biomarkers for the diagnosis of hepatocellular carcinoma	Mariam Zaghloul	Received

THU-152	Systematic review and metanalysis establish dermatologic adverse events as a positive predictor of survival in hepatocellular carcinoma patients treated with sorafenib	Alvaro Diaz-Gonzalez	Received

THU-153	Comparison of the prognosis between non-viral HCC and viral HCC	Kenta Takaura	Received

SAT-153	Peribiliary glands and biliary tree stem cells are involved in the pathogenesis of cholangiocarcinoma arising in patients affected by primary sclerosing cholangitis	Diletta Overi	Received

FRI-153	The impact of platelets on patients with hepatocellular carcinoma	Bernhard Scheiner	Received

SAT-154	TRANSFORMING GROWTH FACTOR-?ETA AND AXL COLLABORATE TO INDUCE CXCL5 AND NEUTROPHIL INFILTRATION IN HEPATOCELLULAR CARCINOMA	Wolfgang Mikulits	Received

THU-154	Risk-stratified management of advanced hepatocellular carcinoma (HCC)	David James Pinato	Received

FRI-154	Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma: A Population-Based Study	Wei-Yu Kao	Received

THU-155	A novel post-surgical prognostic system for colorectal liver metastases treated by preoperative systemic treatment, using tumoral and non tumoral pathological changes, Ras mutation and immunoscore	Pamela Baldin	Received

SAT-155	Mitochondrial VDAC1 based peptide as a new therapeutic agent for hepatocellular carcinoma	srinivas pittala	Received

FRI-155	Virologic control increased overall survival after radiofrequency ablation of hepatocellular carcinoma developed on hepatitis related cirrhosis	Manon Allaire	Received

SAT-156	The role of Lysyl oxidase in tumor microenvironment of primary liver cancer	Monika Lewinska	Received

THU-156	Towards personalised approach in systemic treatment for hepatocellular carcinoma. The value of AGT M235T gene polymorphism	Maria Reig	Received

FRI-156	Clinical and biological features according to fibrosis of HBV related HCC in a Western country	Manon Allaire	Received

SAT-157	The anti-inflammatory receptor TREM2 halts the generation of HCC in mice through the inhibition of liver inflammation and hepatocyte proliferative responses	María Jesús Perugorria	Received

FRI-157	HIV infection adversely influences the natural history of untreated hepatocellular carcinoma (HCC)	David James Pinato	Received

THU-157	A statistical model for survival risk prediction in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment	Sarah Berhane	Received

THU-158	The ALBI and p-ALBI grades predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization (TACE)	Claudia Campani	Received

SAT-158	Functional genomics identified actin cytoskeleton remodeling required for the hypoxia-mediated EMT: a mechanistic link of tumor size to metastasis	Sen-Yung Hsieh	Received

FRI-158	Factors implicated in the risk of developing hepatocellular carcinoma (HCC) in patients with cirrhosis due to HCV. Implications of Sustained Virological Response (SVR)	andres castaño	Received

THU-159	Verification of staging systems and treatment algorithms for hepatocellular carcinoma: perspectives from a Japanese field practice	Sadahisa Ogasawara	Received

SAT-159	The HDAC inhibitorbelinostat enhances the anti-tumor efficacy of immune checkpoint inhibitors ina murine hepatocellular carcinoma model	Pablo Sarobe	Received

FRI-159	INCREASED INTESTINAL PERMEABILITY AND INFLAMMATION ARE ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NAFLD-RELATED LIVER CIRRHOSIS	Francesca Ponziani	Received

THU-160	Temporal changes in recurrent incidences after curative therapies in early stage hepatocellular carcinoma	Akane Kurosugi	Received

SAT-161	OBETICHOLIC ACID, A FXR AGONST , INHIBITS THE CANCEROGENIC POTENTIAL OF PRIMARY HUMAN CHOLANGIOCARCINOMA (CCA) CELLS CULTURES	Sabina Di Matteo	Received

THU-161	The predictive role of procalcitonin for guiding use of antibiotics in HCC patients with post TACE/RFA fever	Sung Bum Cho	Received

FRI-161	Presence of steatosis does not increase the risk of Hepatocellular Carcinoma in patients with Chronic Hepatitis B over long follow-up	CHONG TEIK LIM	Received

SAT-162	Sensitization of cholangiocarcinoma to chemotherapy by SOX17-induced down-regulation of drug export pumps ABCC3 and AGCG2	Jose Marin	Received

THU-162	Combined therapy of transarterial chemoembolizatoin and stereotactic body radiotherapy versus transaterial chemoembolizatoin for < 5m hepatocellular carcinoma: A propensity score matching analysis	Baek Gyu Jun	Received

FRI-162	Sarcopenia is not a predictor of survival or sorafenib toxicity in advanced hepatocellular carcinoma: A Dutch multicenter study	Tim Labeur	Received

THU-163	Out of Milan criteria and worse intetion to treat results at large liver transplant center	Julia Herreras López	Received

FRI-163	The direct comparison between 7th AJCC staging system and 8th AJCC staging system for prediction of survival with Korean multicenter HCC patients	Young-Sun Lee	Received

SAT-163	Defective NKp30-mediated function in hepatocellular carcinoma-infiltrating NK cells	STEFANIA MANTOVANI	Received

SAT-164	Cost-effective target sequencing panel for hepatocellular carcinoma mutational screening	Charlotte Ng	Received

FRI-164	Serum and urine extracellular vesicles contain mRNA biomarkers for primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA)	Ander Arbelaiz	Received

SAT-165	Lack of Osteopontin promotes non-alcoholic steatohepatitis (NASH) and fibrosis, but protects against hepatocellular carcinoma (HCC) progression and mortality in a NASH-HCC mouse model	Alexander Daniel Nardo	Received

THU-165	Comparision of long-term outcome for single small hepatocellular carcinoma between different treatment modalities by size and tumor marker	Dong Hyun Sinn	Received

SAT-166	Canonical inhibition of TransformingGrowth Factor ß Receptor 1 triggers proliferation of hepatocellular carcinoma andis associated with Toll Like Receptor 7 upregulation.	Fatma Mohamed	Received

THU-166	Multimodal and sequential treatmente for hepatocellular carcinoma: how "real-life" complies with international recommendations	Michela Triolo	Received

SAT-167	S100a11 is part of a whole network of tumor suppressors and oncogenes deregulatedearly with hepatic steatosis and contributing to hepatocellular carcinoma development	Cyril Sobolewski	Received

FRI-167	Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: a validation study of the HAP and SAP scores	Francesco Tovoli	Received

SAT-168	Low density neutrophils, as immunosuppressant, increased in HCC patients, highly correlated with advanced stage, predicted stage I HCC recurrence and all patients survival	Chien-Hao Huang	Received

THU-168	Performance of ALBI-PD Model and PALBI Grade in Sorafenib-failed Hepatocellular Carcinoma	Pei-Chang Lee	Received

FRI-168	CD44 rs187115 gene polymorphism in cirrhotic hepatitis C patients with hepatocellular carcinoma	nermeen abdeen	Received

SAT-169	Chemosensitizing effects of beta-caryophyllene oxide in liver cancer	Silvia Di Giacomo	Received

FRI-169	Hepatocellularcarcinoma as second primary malignancy: exposing an overlookedpresentation of liver cancer	Harrys Torres	Received

FRI-170	Adherence to enhanced post-treatment surveillance is associated with increased detection of early stage recurrence after radiofrequency ablation but not surgical management of hepatocellular carcinoma	Yin Chan	Received

SAT-170	Application of patient-derived liver cancer cells for personalized treatment approach: from phenotypic characterization to therapeutic target identification	Darko Castven	Received

SAT-171	Depletion of the HDC/histamine axis ablates tumor formation, angiogenesis, EMT and inflammation in Mdr2 knockout mice	Lindsey Kennedy	Received

THU-172	Transarterial-chemoembolization and hepatocellular carcinoma. A regular interval approach avoids the 10% of the procedures and an optimal survival with the transition to systemic therapy in 80% of the patients	Marco Sanduzzi Zamparelli	Received

SAT-172	High miR-224 expression in cholangiocarcinoma may predict survival	Tímea Szekerczés	Received

FRI-172	Particularities of hepatocellular carcinoma on chronic hepatitis C in the era of all- oral antiviral treatment	ELENA LAURA ILIESCU	Received

FRI-173	Short-term evaluation of hepatocellular carcinoma after locoregional treatment: usefulness of contrast-enhanced ultrasonography	Giulia Gibiino	Received

THU-173	Impact of regorafenib in the clinical practice and identification of second-line treatment orphan patients	Marco Sanduzzi Zamparelli	Received

THU-174	Combined Photodynamic Therapy with Systemic Chemotherapy Improves Survival of Patients with Irresectable Cholangiocarcinoma	Maria Angeles Gonzalez-Carmona	Received

FRI-174	Performance of Wisteria floribunda agglutinin-positive Mac2-binding protein as an HCC biomarker in an ethnically diverse cohort of patients with chronic HBV and HCV	Tomi Jun	Received

THU-175	Outcomes of single or sequential dual modality loco-regional therapies in Hepatocellular carcinoma	Vinay Kumar Balachandrakumar	Received

SAT-175	The role of IL-6 signaling pathway in cholangiocarcinoma	Thi Mai Ly Nguyen	Received

FRI-175	A functional ATG16L1 (T300A) gene variant is associated with increased risk for hepatocellular carcinoma in cirrhosis	Philipp Reuken	Received

THU-176	Clinical features and prognosis of advanced stage hepatocellular carcinoma; verification of diverse progression processes	Masayuki Yokoyama	Received

FRI-176	Serial Changes in Alpha-fetoprotein, Lectin-Bound Alpha-fetoprotein and Des-r-Carboxy Prothrombin in Prospectively Collected Serum Samples before the Diagnosis of Hepatocellular Carcinoma	Jonggi Choi	Received

FRI-177	Sphingolipids: a further step into the detection of early and intermediate hepatocellular carcinoma	Iuliana Nenu	Received

SAT-177	A new insight on the stem cell growth factor beta as astrong predictor of therapy response in hepatocellular carcinoma	Riccardo Patti	Received

THU-177	Soluble urokinase plasminogen activator receptor (suPAR) represents a novel serum biomarker for patients undergoing resection of colorectal liver metastases	Sven Loosen	Received

SAT-178	Disrupted cholesterol synthesis leads to female prevalent hepatocellular carcinoma in transgenic mice	Kaja Blagotinšek Cokan	Received

THU-178	Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with Sorafenib	Giulio Antonelli	Received

FRI-178	A high alpha-fetoprotein slope prior to therapy correlates with poor prognosis of patients with hepatocellular carcinomas.	Carolin Czauderna	Received

THU-179	The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment	Jee-Fu Huang	Received

THU-180	Analyses of intermediate stage hepatocellular carcinoma patients from the point of view of designing clinical trials comparing transarterial chemoembolization and systemic therapies	Keisuke Koroki	Received

SAT-180	Sorafenib/Regorafenib resistance and BH3-mimetics efficacy in hepatocellular carcinoma treatment is determined by mitochondrial changes in the BCL-2 profile.	Anna Tutusaus	Received

THU-181	IMPACT OF BCLC TREATMENT STAGE MIGRATION IN THE SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA	Silvia Acosta-López	Received

SAT-181	MALDI IMAGING OF HEPATOCHOLANGIOCARCINOMAS: A CLUE TO TACKLE TUMOR HETEROGENEITY. PRELIMINARY RESULTS	Elia Gigante	Received

FRI-181	Clinical Presentation and Survival of Asian and Non-Asian Patients with HBV-related Hepatocellular Carcinoma (HBV-HCC): Results of 767 United States patients with long-term follow-up.	Joseph Hoang	Received

THU-182	ALBI is an independent predictor ofsurvival in resected patients with HCC	Philippe Kolly	Received

THU-183	Portal vein tumor thrombosis has a direct impact on liver function.	Roman Klöckner	Received

FRI-183	Monofocal HCC: Milan Criteria or BCLC staging system? An analysis of the ITA.LI.CA. database	Giulia Peserico	Received

SAT-183	Aspecific ECM composition regulates Smad dependent - TGFbeta1–induced EMT response in HepG2 cells engineered in cirrhotic and healthyliver 3D scaffolds	Krista Rombouts	Received

FRI-184	Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma	Sebastian Schotten	Received

SAT-184	Analysis of HBV DNA Integration in Tumor and non-Tumor Liver Tissues by a High-Throughput Viral Integration Detection Method.	Deborah D´Aliberti	Received

THU-184	A Novel Model for the Outcome Prediction of Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma with or without Impaired Hepatic Function	Hwi Young Kim	Received

SAT-185	New targets for hepatocellular carcinoma therapy: the Myc/PRMT5/RNAP II circuit	Cristiana Porcu	Received

THU-185	Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions inthe liver.	Sherief Abd-Elsalam	Received

FRI-185	Risks of Hepatocellular carcinoma and cirrhosis-associatedcomplications in patients with rheumatoid arthritis receiving biologics: a10-year population-based propensity-score matched cohort study	Ching-Sheng Hsu	Received

SAT-186	Novel microRNA-based drug CD5-2 reduces liver cancer development in multi-drug-resistance gene-2 knockout mice	Ken Liu	Received

FRI-186	Risk assessment of hepatocellular carcinoma in chronic liver disease patients with a combination of liver stiffness measurement and controlled attenuation parameter by FibroScan	Kenichi Morikawa	Received

SAT-187	KRAS-dependent AKT signaling drives hepatocyte proliferation to promote tumor development in a genetic model of liver cancer	Thomas Rösner	Received

FRI-187	Single-cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma	Delia D´Avola	Received

THU-187	A comparison of surgical resection and transarterial chemoembolization for solitary hepatocellular carcinoma larger than 10cm: A propensity score matching analysis	Hsiao-Sheng Lu	Received

SAT-188	The impact of the epigenetic writer LSD1in the cell cycle control in liver fibrosis and hepatocellular carcinoma	Lingyu Wang	Received

THU-188	Phase II Trial Using Combination of TACE and SBRT for Unresectable Single Large HCC: Preliminary Report	Michael Buckstein	Received

SAT-189	Sofosbuvir directly promotes the clonogenic capability of human hepatocellular cancer cells	Jiaye Liu	Received

THU-190	Ubr Ubiquitin ligases as modulators of inflammation in hepatocellular carcinoma	Dominique Leboeuf	Received

THU-191	Extrahepatic autoimmune diseases in patients with autoimmune hepatitis and their relatives: a Danish nationwide family cohort study	Lisbet Grønbæk	Received

SAT-191	Protective effect of statins in cirrhosis might be dependent on common genetic risk variants	Matthias Reichert	Received

FRI-191	Obeticholic acid response in primary biliary cholangitis associated with differential expression of antigen presentation, Wnt signalling and mRNA splicing	Andrew L. Mason	Received

THU-192	Pregnancy and birth outcomes in a Danish nationwide cohort of women with autoimmune hepatitis and matched population controls	Lisbet Grønbæk	Received

FRI-192	TGR5 modulates gallbladder function and bile acid pool composition : potential hepatoprotective impact in mice	Bidault Jourdainne Valeska	Received

SAT-193	The mechanism of irreversibility of late stage cirrhosis	Ian Wanless	Received

FRI-193	NLRP3 deletion leads to decreased inflammation and prevents fibrosis formation in mice after chronic bile duct ligation.	Mick Frissen	Received

THU-193	Autoantibodies against Huntingtin-interacting protein 1-related protein are superior to conventional autoantibodies in diagnosing autoimmune hepatitis in children.	Richard Taubert	Received

THU-194	Time Trends in Liver Transplantation for Primary Biliary Cholangitis in Europe over the Past Three Decades	Maren Harms	Received

FRI-194	Activation of pyruvate kinase isoform M2 (PKM2)in myeloid cells protects from Concanavalin A-mediated liver injury	Andrea Horst	Received

SAT-194	Acellular growth retardation ability (AGRA), a novel biomarker for humoral immune function, predicts the occurrence of severe bacterial infections in cirrhosis	Angela Horvath	Received

SAT-195	Assessing Baveno VI criteria with a new point-shear wave elastography technique: the BAVElastPQ study	Giulia Gibiino	Received

FRI-195	Carcinoembryonic antigen-relatedcell adhesion molecule 1 (Ceacam1) controls IL-2-dependent regulatory T cell induction in immune-mediated hepatitis	Andrea Horst	Received

FRI-196	The suppressive effect of Interleukin-17-expression in antigen specific CD8+ T cells in acute experimental cholangitis in mice	Stephanie Stein	Received

SAT-196	The efficacy and clinical outcome of transjugular intrahepatic portosystemic shunts (TIPS) in the management of ectopic variceal bleeding: a multicenter retrospective study	Rosalie Oey	Received

THU-197	Biliary IL8 is a marker for disease progression and risk for biliary neoplasia in primary sclerosing cholangitis	Martti Färkkilä	Received

SAT-197	Outcomes of pregnancy in women with cirrhosis - a national, population-based cohort study	Hannes Hagström	Received

SAT-198	Prevalence and resistance rates of infections with enterococci in patients with cirrhosis	Theresa Bucsics	Received

FRI-198	FXR Agonist Obeticholic Acid Increases Gallbladder FGF19 in Gallstone Patients	Samer Al-Dury	Received

THU-198	Pruritus strongly reduces quality of life in PBC patients - real life data from a large national survey	Andreas E Kremer	Received

THU-199	Functional connectivity reveals altered activation of distinct brain areas in pruritus of cholestasis	Andreas E Kremer	Received

SAT-199	Effectiveness of "early" TIPS implantation vs "late" TIPS vs standard endoscopic treatment for acute variceal bleeding in patients with liver cirrhosis	Theresa Bucsics	Received

FRI-199	Loss of BSEP protects MDR2/ABCB4 KO mice from cholestatic liver injury by altering bile acid profile and signaling	Claudia Fuchs	Received

THU-200	A stepwise algorithm for biliary brush cytology shows high diagnostic performance in primary sclerosing cholangitis	Erik von Seth	Received

FRI-200	The faecal microbiome of patients with primary sclerosing cholangitis has a characteristic signature across different geographic regions	Timur Liwinski	Received

FRI-201	The faecal microbiome of patients with autoimmune hepatitis is characterised by reduced diversity and is different from healthy subjects and patients with ulcerative colitis	Timur Liwinski	Received

THU-201	VCAM-1 and soluble CD-163 as novel non-invasive markers of liver fibrosis in patients with autoimmune hepatitis - a prospective study	Maciej Janik	Received

SAT-201	The area of the paarspinal muscle mass in patients with cirrhosis although not different from controls predicts cirrhosis-associated complications and death in a large mono-centric study	Cornelius Engelmann	Received

THU-202	Rituximab treatment experience in patients with complicated type 1 autoimmune hepatitis in Europe and North America	Nwe Ni Than	Received

SAT-202	TLR9-mediated immune sensing of bacterial DNA in decompensated cirrhosis is stage-dependent	Eihab Al-Herwi	Received

FRI-202	Different bile acids display distinct ability to trigger Nlrp3 inflammasome activation in a cell-dependent manner contributing to cholestatic liver injury and fibrosis	Maria Inzaugarat	Received

SAT-203	Longitudinal outcomes of the application of non-selective beta-blockers in portal hypertension: Are low-dose non-selective beta-blockers effective?	Seong Hee Kang	Received

THU-203	Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years	Anna Reig	Received

FRI-204	A novel CCL24 blocking monoclonal antibody ameliorates liver injury in experimental models of cholestasis	Adi Mor	Received

THU-204	Histologic Stage is a Stronger Predictor of Transplant Free Survival than APRI and FIB-4 in Patients with Primary Biliary Cholangitis	Aliya Gulamhusein	Received

THU-205	Morning bright light treatment for sleep-wake disturbances in Primary Biliary Cholangitis (PBC)	Daniel Zaldumbide	Received

SAT-205	Prognosis after abdominal surgery in patients with idiopathic non-cirrhotic portal hypertension: a multicenter retrospective study	Laure ELKRIEF	Received

FRI-205	Generation of a novel mouse model for the study of autoimmune liver disease overlap syndrome	Sina Fuchs	Received

THU-206	Novel protein biomarkers in serum extracellular vesicles for the diagnosis of primary sclerosing cholangitis (PSC) in patients with ulcerative colitis (UC)	Ainhoa Lapitz	Received

FRI-206	Anticholestatic mechanisms of ursodeoxycholic acid in inflammatory cholestasis induced by lipopolysacharide	María Valeria Razori	Received

SAT-206	Addition of simvastatin to standard treatment is safe, effective and improves quality of life in patients with decompensated cirrhosis	Alberto Muñoz	Received

SAT-207	Characterization of systemic inflammatory response in hepatorenal syndrome in cirrhosis. A major role for il-6, TNF-alpha, and VCAM	Cristina Sole	Received

FRI-207	Fine tuning of SIRT1 expression is essential to protect the liver from cholestasis	Naiara Beraza	Received

SAT-208	Skeletal Muscle Index (SMI) Indicates Mortality Risk More Accurately than Psoas Muscle Index (PMI) in Patients with Cirrhosis. From The FLEXIT Consortium.	Aldo J Montano-Loza	Received

FRI-208	Leukemia inhibitory factor induces cholangiocyte proliferation and corrects the impaired bile duct proliferation in sortilin-deficient mice following cholestatic injury	Isabel Zvibel	Received

SAT-209	Loss of Subcutaneous Adipose Tissue Associates with Higher Mortality Risk in Patients with Cirrhosis	Aldo J Montano-Loza	Received

THU-209	Differentiation of acute icteric autoimmune hepatitis from idiosyncratic drug-induced liver injury by histological and biochemical criteria	Marcial Sebode	Received

FRI-209	Relapse of autoimmune hepatitis is associated with a low intrahepatic ratio of regulatory T cells to cytotoxic T cells prior to immunosuppression withdrawal	Finn Derben	Received

SAT-210	Assessment of biventricular function in patients with decompensated cirrhosis and hepatopulmonary syndrome	Stergios Soulaidopoulos	Received

FRI-210	Experimental autoimmune hepatitis in mice is associated with formation of ectopic lymphoid tissue in the liver	Max Preti	Received

THU-210	Patients with primary biliary cholangitis exhibit reduced hippocampal volume and MRI evidence of neuroinflammation	Victoria Mosher	Received

SAT-211	Loss of colonization resistance in cirrhosis facilitates proton pump inhibitor-associated oralization of the colonic microbiome	Florian Rainer	Received

THU-211	Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis	Carla Fiorella Murillo Perez	Received

THU-212	Risk factors for hepatocellular carcinoma in a large cohort of patients affected by primary sclerosing cholangitis.	Francesca Saffioti	Received

SAT-212	THE AMELIORATION OF MUSCLE WASTING LEADS TO THE IMPROVEMENT OF COGNITIVE IMPAIRMENT AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT: A PROOF OF CONCEPT THAT SARCOPENIA AND HEPATIC ENCEPHALOPATHY ARE CAUSALLY RELATED	Stefania Gioia	Received

FRI-212	Cu isotope ratio shifts in common bile duct ligated mice and correlates with the degree of cholestatic-induced liver disease	Sanne Van Campenhout	Received

SAT-213	NON CIRRHOTIC PORTAL HYPERTENSION SECONDARY TO OXALIPLATIN THERAPY : INCIDENCE AND PRESENTATION	Stefania Gioia	Received

THU-213	Optimal institution of azathioprine maintenance therapy in autoimmune hepatitis: a multicenter cohort study	Simon Pape	Received

SAT-214	The Cost-Effectiveness of Albumin in the Treatment of Decompensated Cirrhosis in Italy, Spain and Germany	Paolo CARACENI	Received

FRI-214	The atypical antidepressant mirtazapine is hepatoprotective in a mouse model of immune-mediated hepatitis	Wagdi Almishri	Received

FRI-215	Fine-mapping and colocalisation analysis of GWAS risk loci in Primary Sclerosing Cholangitis suggests role for proto-oncogene ETS2 in disease pathogenesis	Elizabeth Goode	Received

THU-215	Biochemical response to ursodeoxycholic acid predicts histologic primary biliary cholangitis progression	Tadashi Namisaki	Received

SAT-215	The role of HbA1c as a risk factor for the development of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis	Tammo Tergast	Received

FRI-216	Hypersensitivity and constitutive activation of the IL-12/STAT4 pathway in NK cells in Primary Biliary Cholangitis: a novel mechanism	Theresa Hydes	Received

FRI-217	Deletion of tumor necrosis factor alpha receptor 1 leads to an increased Th17 cell response in the chronically inflamed liver	Laura Berkhout	Received

FRI-218	Lysophosphatidic acid activates peripheral glia cells via LPA receptor 1	Katharina Wolf	Received

THU-218	Pre-treatment risk stratification in primary biliary cholangitis: a predictive model to guide first-line combination therapy	Marco Carbone	Received

SAT-218	VALIDATION OF THE BAVENO CRITERIA FOR ENDOSCOPIC SURVEILLANCE OF VARICES IN CHOLESTASIC DISEASES	STEPHANIE TASAYCO	Received

SAT-219	High-dose but not low-dose enoxaparin substantially improves survival in cirrhotic patients with portal vein thrombosis	Laura Turco	Received

FRI-219	Intrahepatic type II natural killer T cells switch to a pro-inflammatory cytokine profile in patients with autoimmune hepatitis	Marcial Sebode	Received

THU-219	Sustained biochemical response to oral antibiotics in pediatric PSC and ASC are correlated to changes in gut microbiota during therapy	Pauline Sambon	Received

THU-220	Primary biliary cholangitis specific T cell receptors on N-Ras high CD4 T cells	Ryo Nakagawa	Received

SAT-220	Higher in-hospital and post-discharge mortality and hospital charges in cirrhotic patients with acute respiratory illness in the United States	Pauline Nguyen	Received

FRI-220	Human chorionic-plate-derived mesenchymal stem cells restore hepatic lipid metabolism in a rat model of bile duct ligation.	Yun Bin Lee	Received

THU-221	Validation of various prognostic models in primary biliary cholangitis in Korean patients	Jeong-Ju Yoo	Received

FRI-221	In vitro rescue of ABCB11 nonsense mutations : induction of a readthrough of premature stop codons	Rachida AMZAL	Received

THU-222	Imaging Features of Macroregenerative Nodules (MRN) in Primary Sclerosing Cholangitis: MR imaging characteristics.	Andres Morgado	Received

SAT-222	Assessment of portal hypertension evolution in HCV cirrhosis patients with baseline large oesophageal varices after sustained virological response	Antonio Olveira Martin	Received

FRI-222	The anti-inflammatory receptor TREM2 protects the liver from cholestatic injury in mice	Ibone Labiano	Received

SAT-223	The impact of hepatic steatosis on portal hypertension	Bernhard Scheiner	Received

THU-223	Effect of nalfurafine hydrochloride for refractory pruritus in patients with primary biliary cholangitis: a multicenter, post-marketing, single-arm, prospective study	Minami Yagi	Received

SAT-224	Controlled attenuation parameter (CAP) does not predict hepatic decompensation in patients with advanced chronic liver disease	Bernhard Scheiner	Received

FRI-224	Low-dose Interleukin-2 Expands the Number of Circulating Regulatory T cells in Patients with Treatment-Refractory Autoimmune Hepatitis	Tiong Yeng Lim	Received

SAT-225	Thromboelastography guided blood product transfusion in cirrhosis patients with acute variceal bleeding: a Randomized Controlled Trial	Gyanranjan Rout	Received

THU-226	Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis - the Global PBC Study Group	Willem J Lammers	Received

FRI-226	Deep immunophenotyping of liver infiltrating lymphocytes reveals distinct differences in the T cell compartment of patients with Primary Sclerosing Cholangitis	Tobias Poch	Received

SAT-227	Non-selective beta-blockers increase liver mortality when MELD is =12 in a prospective 5 year follow-up cohort of alcoholic cirrhosis	Paul Cales	Received

THU-227	A Dose-Response Relationship in the Association between Ursodeoxycholic Acid Treatment and Prolonged Transplant-free Survival in Primary Biliary Cholangitis	Adriaan Van der Meer	Received

THU-228	Incidence of autoimmune hepatitis is increasing, while primary biliary cholangitis and primary sclerosing cholangitis have remain unchanged: a population-based study	Mehul Lamba	Received

SAT-228	Men have higher mortality in cirrhosis: outcomes by gender and etiology in a large, diverse cohort	Apurva Yeluru	Received

FRI-228	Necroptosis signalling pathway in hepatic fibrosis; role of receptor-interacting serine-threonine kinase 3 and mixed lineage kinase domain-like in cirrhosis	Waqar Saeed	Received

FRI-229	Role of Toll-like receptor 4 (TLR4) in regulating severity of hyperammonemia and gene expression of urea cycle enzymes	Annarein Kerbert	Received

THU-229	Autoantibody-negative autoimmune hepatitis presents more commonly with advanced fibrosis or cirrhosis	Mehul Lamba	Received

SAT-229	Prior or On-treatment Infection Does Not AffectResponse to Treatment or Survival in Patients with Hepatorenal Syndrome Type 1(HRS-1)	Florence Wong	Received

SAT-230	Anticoagulant treatment for atrial fibrillation and decompensation rate in patients with liver cirrhosis	Irina Girleanu	Received

THU-230	Prognosis in patients with primary biliary cholangitis based on histological stage at diagnosis. A nationwide population-based study	Lars Bossen	Received

FRI-230	Regulatory T cells modulate the concentration of short chain fatty acids and the Th function in response to induced bacterial traslocation episodes, and improve the integrity of the gut barrier in an experimental cirrhosis model.	Oriol Juanola	Received

FRI-231	Characterization of the Protective Effects of Yaq-001on Organ Injury in Cirrhosis	Francesco De Chiara	Received

SAT-231	Decreased Model for End-Stage Liver Disease (MELD) score after antiviral treatment predicts reduced risk of mortality and hepatic events in chronic hepatitis B related cirrhosis - a study of 1,729 subjects	Lai-Hung, Grace Wong	Received

SAT-232	Propranolol Treatment Associated with Better Survival and Reduced Sepsis in Cirrhotic Patients with Hepatic Encephalopathy	Pei-Chang Lee	Received

THU-232	Chloroquine in monotherapy is safe and effective for induction of remission in anti-SLA/LP positive patients with autoimmune hepatitis	Débora Terrabuio	Received

FRI-232	Systemic inflammation and portal vein thrombosis in gastroesophageal varies	xiaoquan HUANG	Received

THU-233	Health-Related Quality of Life in patients with autoimmune hepatitis	Atsushi Takahashi	Received

SAT-233	Six-minute Walk Test and Sarcopenia in Predicting Mortality in Patients with Cirrhosis	ThucNhi Dang	Received

THU-234	PREGNANCY AND AUTOIMMUNE HEPATITIS: PRESENTATION AND OUTCOMES	Laura Patricia Llovet	Received

SAT-234	The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma	Hsiao-Sheng Lu	Received

FRI-234	Simvastatin-loaded polymeric micelles are a new, safe and effective drug delivery system targeting liver sinusoidal endothelial cells	Diana Hide	Received

THU-235	EFFICACY AND SAFETY OF CALCINEURIN INHIBITORS AS SALVAGE THERAPY IN PATIENTS WITH AUTOIMMUNE HEPATITIS	Simone Strasser	Received

FRI-235	Transcriptome analysis of human and murine cirrhotic livers identifies shared molecular pathways as potential targets to enhance cirrhosis regression	Erica Lafoz	Received

SAT-236	Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in cirrhosis: a systematic review and meta-analysis of randomized controlled trials	Roger F. Butterworth	Received

THU-236	RISK STRATIFICATION USING TRANSIENT ELASTOGRAPHY AND THE NEW SCORING SYSTEMS FOR PATIENTS WITH PRIMARY BILIARY CHOLANGITIS	Lisa Perini	Received

FRI-236	In cirrhotic rats, mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis by modulating oxidative stress and mitophagy.	Saadet Turkseven	Received

SAT-237	Deleterious effect of proton pump inhibitors on the disease course of cirrhosis	Zsuzsanna Vitális	Received

THU-237	Independent Predictors of Primary Biliary Cholangitis (PBC) at High Risk for Progressive Course in the United States: Data from a Large- Real World Database	Zobair Younossi	Received

FRI-237	Ascites NK cells are phenotypically distinct from blood and liver NK cells in patients with liver cirrhosis and become activated by bacterial stimulation in-vitro and during spontaneous bacterial peritonitis	Philipp Lutz	Received

SAT-238	The impact of pulmonary arterial hypertension therapy in patients with portopulmonary hypertension: a single tertiary center cohort analysis	Frederik Nevens	Received

SAT-239	NON-SELECTIVE BETA-BLOCKERS REDUCE CARDIAC SYSTOLIC FUNCTION AND IMPAIR RENAL FUNCTION IN PATIENTS WITH REFRACTORY ASCITES	Luis Téllez	Received

FRI-239	Real world experience of lusutrombopag for thrombocytopenia in patients with liver cirrhosis	Hitomi Takada	Received

FRI-240	Chronic liver damage causes a reduction in the number and a dysfunction of the activity of liver resident macrophages	ELISA POSE	Received

SAT-240	HIGH RISK OF ESOPHAGEAL VARICES IN PATIENTS WITH FONTAN SURGERY: THE VALDIG FONLIVER STUDY	Luis Téllez	Received

SAT-241	Distinct MELD Trajectories in Liver Transplant Candidates with Hepatitis C and NASH	Allison Kwong	Received

FRI-241	An Immuno-metabolic phenotype of Acute-on-Chronic Liver Failure predicts early mortality	Rabiya Zia	Received

FRI-242	Etiology-specific hemostatic profiles in cirrhosis	Sarah Bos	Received

FRI-243	Prediction of Blood Ammonia Levels in Modeled Human Liver Dysfunction and Application to Gut-Restricted Ammonia Lowering Therapeutics	Christine Brew	Received

SAT-243	Effect of vardenafil on portal hemodynamics in patients with mild and moderate liver dysfunction: a randomized, placebo-controlled trial	Rafael Paternostro	Received

FRI-244	POLYMORPHISMS IN TOLL-LIKE RECEPTORS IDENTIFY A DEFECTIVE OXIDATIVE RESPONSE AND A REDUCTION IN THE REGULATORY T CELL POPULATION IN PATIENTS WITH CIRRHOSIS AND NON-INFECTED ASCITES	Paula Piñero	Received

SAT-244	Varices on CT is the surrogate of clinically significant portal hypertension and can predict survival in patients with cirrhosis	Dong Ho Lee	Received

SAT-245	Predictors of Endoscopic High Risk EsophagealVarices in Compensated Cirrhosis: Can we Avoid Fibroscan?	Julian Hercun	Received

THU-245	Class III (morbid) obesity is an independent risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis	Vinay Sundaram	Received

FRI-246	Effectiveness of a practical nutritional intervention in advanced liver disease: a prospective study	Dalila Costa	Received

THU-246	Regional variations in the development of acute-on-chronic liver failure (ACLF) in patients with cirrhosis and bacterial infections	Florence Wong	Received

THU-247	Number of organ failures is a better predictor of waitlist mortality in those who die within 30 days of listing for liver transplantation	Paul J. Thuluvath	Received

SAT-247	Second-look endoscopy and prolonged use of proton pump inhibitor and octreotide after variceal ligation reduce early bleeding rate in cirrhosis with large gastroesophageal varices: a single-blinded, single-centered and randomized controlled trial	Anjiang Wang	Received

THU-248	Impact of receptor interacting protein kinase 3 levels on acute on chronic liver failure progression	Takayuki Kondo	Received

FRI-248	The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH	Philipp Schwabl	Received

SAT-248	Uncontrolled diabetes increases all causes of mortality and particularly cardiovascular death in patients with cirrhosis	Fatima Higuera-de La Tijera	Received

FRI-249	GENETIC FACTORS OF HEPATIC ENCEPHALOPATHY ON PATIENTS WITH CIRRHOSIS: CANDIDATE GENE STUDY	Antonio Gil-Gomez	Received

THU-250	Combinations of inflammatory markers, soluble (s)CD163, mannose receptor (sMR) and neutrophil gelatinase associated lipocalin (NGAL), predicts mortality in patients with acute-on-chronic liver failure	Henning Grønbæk	Received

FRI-250	LSECtin and CD206 participate in the regulation of the hepatic inflammatory response to E coli in a model of cirrhosis	Esther Caparrós	Received

SAT-250	Increasing Burden of Hepatic Encephalopathy among Hospitalized Adults, With Significantly Higher Risk of In-Hospital Mortality in African Americans: An Analysis of the 2007-2013 Nationwide Inpatient Sample	Grishma Hirode	Received

FRI-251	Changes of bile acids profile in different etiologies of liver cirrhosis and its association with neutrophil response	Irina Komarova	Received

THU-252	Early management of critically ill cirrhotic patients admitted in ICU for gastrointestinal bleeding: wait day 3 to avoid taking a bad decision.	Lucy Meunier	Received

SAT-253	Functional polymorphisms of innate immunity receptors are not risk factors for non-SBP type bacterial infections in cirrhosis	Tamas Tornai	Received

THU-253	Dynamic assessment is superior to baseline assessment in prognostication of patients with acute on chronic liver failure	Sahaj Rathi	Received

THU-254	Acute on Chronic Liver Failure-Comparison of patients identified by the European Association for the study of the Liver and the North American Consortium for study of End-Stage Liver Diseases	Zita Galvin	Received

SAT-254	The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis	Ji Jade King	Received

FRI-254	Occult hepatitis B infection in hepatocellular carcinoma patients with negative HBsAg	Danny Wong	Received

SAT-255	MELD-score underestimates mortality in patients with nosocomial spontaneous bacterial peritonitis	Markus Kimmann	Received

THU-255	Liver transplantation in patients admitted to intensive care with acute-on-chronic liver failure	Eleni Theocharidou	Received

FRI-255	Non-linear association between serum hepatitis B virus DNA levels and hepatocellular carcinoma risk in treatment-naive, non-cirrhotic chronic hepatitis B patients	Gi-Ae Kim	Received

FRI-256	Hepatitis B Splice Variants are strongly associated with and are indeed predictive of hepatocellular carcinoma	Peter revill	Received

SAT-258	Development and predictive validity of the Cirrhosis-associated Ascites Symptom Scale: A cohort study of 103 patients.	Agnete Riedel	Received

FRI-258	Antiviral therapy can be avoided in most HBeAg-negative Caucasian patients in the Gray Zone	Martin Bonacci	Received

SAT-259	Clinical, paraclinical and MR-spectroscopy profile in cirrhotic and non-cirrhotic portal hypertension patients with minimal hepatic encephalopathy	Bertrand Hermann	Received

FRI-259	Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in chronic hepatitis D	Antonella Olivero	Received

THU-259	Invasive fungal infections in Acute on chronic liver failure - An Asia Pacific experience from the AARC consortium	Sunil Taneja	Received

SAT-260	Multimodal approach including MR-spectroscopy for the diagnosis of minimal hepatic encephalopathy	Bertrand Hermann	Received

FRI-260	Soluble cytotoxic T-lymphocyte-associated antigen-4 (sCTLA-4) and soluble programmed cell death protein-1 (sPD-1) are predictive immune checkpoint seromarkers for spontaneous functional cure of chronic hepatitis B with opposite effects	Hwai-I Yang	Received

THU-261	Hyperkalemia influences the outcome of patients with cirrhosis with acute decompensation (AD) and acute on chronic liver failure (ACLF)	Andres Cardenas	Received

SAT-261	KINETICS OF POLYMORPHONUCLEAR COUNT IN ASCITIC FLUID. PERSISTENT SPONTANEOUS BACTERIAL PERITONITIS.	Alberto Amador	Received

THU-262	Impact of organ failure in patients with acute on chronic liver failure (ACLF) and the newly defined AARC liver failure score in predicting 90 days survival-results from APASAL-ACLF research consortium (AARC)	Apurva Pande	Received

SAT-262	Impact of an antimicrobial stewardship policy on the reduction of empirical antibiotic treatment failure and the spread of multidrug-resistant organisms in hospitalized cirrhotic patients	simone incicco	Received

FRI-262	Identifying epigenetic markers for characterization of host response to hepatitis B virus infection during the development of hepatocellular carcinoma	wan-jung wu	Received

SAT-263	Outpatient terlipressin infusion increases dietary intake and functional muscle strength in patients awaiting liver transplant	Brooke Chapman	Received

FRI-263	External validation of clinical scoring system for the prediction of hepatocellular carcinoma in chronic hepatitis B treated by nucleotide/nucleoside analogue	Masayuki KUROSAKI	Received

SAT-264	Dynamic Visual Processing in Patients with Decompensated Cirrhosis	Katherine Wong	Received

FRI-264	Monitoring patients with a resolved hepatitis B virus infection for HBV reactivation	Akihiro Tamori	Received

THU-265	Outcome of bacterial infections complicated or not by acute-on-chronic liver failure in patients with cirrhosis admitted to hospital for acutedecompensation.	Michele Bartoletti	Received

SAT-265	The physical component of the SF-36 Quality of Life tool is an independent predictor of mortality in patients with severe ascites	Daniel Zaldumbide	Received

FRI-265	Relationship between hepatitis B core-related antigen and chronic hepatitis B outcome in HBeAg negative patients: a 10-year longitudinal study	Wai Pan To	Received

FRI-266	Real-world rates of hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B (CHB): a systematic review, conventional aggregated data meta-analysis (ADMA) and individual patient data meta-analysis (IPDMA)	Donghak Jeong	Received

SAT-266	Clinical frailty scale as a novel tool predicts unplanned hospitalisation and/or death in outpatients with cirrhosis.	ANIRUDDHA PRATAP SINGH	Received

THU-266	Typing acute-on-chronic liver failure according to World Gastroenterology Organization working party definition in HBV-related patients	Xiaoting Tang	Received

FRI-267	Association of common polymorphism in the Interleukin 1 beta gene with Hepatitis B virus-related hepatocellular carcinoma in Caucasians	Janett Fischer	Received

SAT-267	RELATIONSHIP BETWEEN VISCERAL FAT AND PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS	Marta Hernández Conde	Received

THU-268	Relative adrenal insufficiency in acute-on chronic liver failure - a new futility marker?	Anca Trifan	Received

SAT-268	Terlipressin for variceal bleeding induces severe plasma sodium disturbances in non-cirrhotic portal hypertension	Peter Lykke Eriksen	Received

FRI-268	Effective hepatitis B vaccination by serologic results in the United States: a population-based study from 1999-2016	Michael Huan Le	Received

THU-269	The Combination of Acute-on-Chronic Liver Failure (ACLF) as defined by EASL-CLIF Consortium Definition and MELD Can Predict Post-transplant Survival in Patients with ACLF	Uchenna Agbim	Received

SAT-269	Outcome after the use of SX-ELLA Danis bleeding stents for refractory variceal bleeding- a Vienna Multicenter Experience	Nikolaus Pfisterer	Received

FRI-269	Suboptimal rates of effective hepatitis B vaccination in adults at high risk of infection in the United States from 1999-2014	Michael Huan Le	Received

SAT-270	The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites	Nikolaus Pfisterer	Received

THU-270	Hemophagocytic Lymphohistiocytosis (HLH) in patients of Acute on chronic liver failure -Results of multination study from APASL-ACLF Research Consortium (AARC)	Harsh Vardhan Tevethia	Received

FRI-270	Droplet digital PCR quantitation of HBV cccDNA pool and transcriptional activity in long-term nucleos(t)ide analogue treated patients	Aurore Inchauspé	Received

THU-271	Human beta-defensin-1 is a highly predictive marker of mortality in patients with acute-on-chronic liver failure	Ilianna Mani	Received

THU-272	Thromboelastography parameters in acute on chronic liver failure	Sandeep Goyal	Received

SAT-272	Hemodynamic disturbances across different stages of decompensated cirrhosis and influencie on outcomes	Marta García Guix	Received

FRI-272	Combination of HBV serological markers to predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg negative Chronic Hepatitis B	Romina Salpini	Received

SAT-273	Prevalence and clinic impact of rectal colonization by multidrug-resistant bacteria in descompensated cirrhosis	Maria Hernandez-Tejero	Received

THU-273	Features of levels of neurospecific proteins in patients with hepatic encephalopathy	Nataliia Dynnyk	Received

THU-274	Non inferiority of combination of slow continuous albumin,furosemide with low dose Terlipressin with Noradrenaaline infusion in ACLF patients in comparison to slow continuous albumin , furosemide and Terlipressin	Gaurav Pandey	Received

SAT-274	Improving assessment of hepatic encephalopathy in outpatient clinics	Floranne Hansa	Received

FRI-274	Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy	Minjong Lee	Received

THU-275	Impact of response guided aggressive pharmacological therapy with slow continuous albumin, furosemide and terlipressin infusion in chronic liver failure consortium acute on chronic liver failure score	Gaurav Pandey	Received

FRI-275	Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection	Gian Paolo Caviglia	Received

SAT-275	PROTON PUMP INHIBITORS INCREASE THE RISK OF MINIMAL AND OVERT HEPATIC ENCEPHALOPATHY AND THEY ARE ASSOCIATED WITH HIGH MORTALITY IN CIRRHOTIC PATIENTS.	SILVIA NARDELLI	Received

THU-276	Impact of Clostridium difficile 027 ribotype in decompensated cirrhotic patients	Ainhoa Fernandez	Received

SAT-276	The time trend of hospital admissions, inpatient mortality rate, and hospital cost of hospitalizations associated with cirrhosis in the United States: an analysis on the National Inpatient Sample	Donghak Jeong	Received

FRI-276	Pan-genotypic loop-mediated isothermal amplification assay (LAMP) for HBV: a simple, rapid and affordable point-of-care test to semi-quantify HBV DNA	Yusuke Shimakawa	Received

SAT-277	Validation and modification of Baveno criteria to rule out high- risk varices in patients with compensated cirrhosis	VARUN RAVINDRA TADKALKAR	Received

FRI-277	Basal core promoter mutations as potential predictors of an enlarged intrahepatic HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B infection	Luna Colagrossi	Received

SAT-278	Outcomes of intrahepatic porto-systemic shunt in the treatment of portal vein thrombosis: a systematic review and meta-analysis	Susana Rodrigues	Received

SAT-279	Clinically significant portal hypertension in chronic liver disease: always cirrhosis?	Susana Rodrigues	Received

FRI-279	Early on-treatment alanine aminotransferase (ALT) normalization reduces risk of hepatic events in patients with chronic hepatitis B	Lai-Hung, Grace Wong	Received

SAT-280	Screening of esophagogastric varices: performance of the "Expanded Baveno VI criteria" and the "platelet 150/MELD 6" strategy in all etiology compensated advanced chronic liver disease	Giulia Tosetti	Received

FRI-280	Occult Hepatitis B infection is frequent and a risk factor of advanced liver disease in The Gambia, West Africa	Gibril Ndow	Received

SAT-281	Combined elastin and collagen proportionate area (ECPA) sub-classifies cirrhosis and predicts clinical outcomes	Avik Majumdar	Received

SAT-282	Transjugular Intrahepatic Portosystemic Shunt (TIPS) is highly effective in patients with a MELD score < 20 and does not require routine Doppler ultrasound follow-up	Koos de Wit	Received

THU-282	Behavioral and clinical factors and Direct Acting Antiviral effectiveness in HCV/HIV co-infection; clinical experience from the TRIO network.	Gregory Huhn	Received

FRI-282	Long-term outcomes and significance of HBeAg Seroclearance in Chronic Hepatitis B: Novel Predictive Scores for HCC and HBsAg seroclearance	Yan Yue James Fung	Received

SAT-283	Efficacy of Liver Stiffness Measurement and Platelet Count in Screening for High Grade Varies in Patients with Cirrhosis.	Ashish Agarwal	Received

FRI-283	Serum WFA+-M2BP level as a diagnostic marker of HBV-related HCC: A case-control study	Natthaya Chuaypen	Received

THU-283	HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy.	Vincenza Calvaruso	Received

THU-284	Therapy with DAAs in patients with chronic hepatitis C and advanced chronic kidney disease: Real-world experience from the German Hepatitis C-Registry (DHC-R)	Johannes Wiegand	Received

FRI-284	The incidence of hepatocellular carcinoma in hepatitis B virus infected persons of different origins, living in Sweden	Ann-Sofi Duberg	Received

THU-285	Uniform addition of ribavirin to sofosbuvir/velpatasvir for genotype 3 patients with cirrhosis: real world outcomes	Alison Boyle	Received

FRI-285	THE EFFICACY OF A COMPUTER ALERT PROGRAMME FOR INCREASING HEPATITIS B VIRUS SCREENING RATES BEFORE STARTING IMMUNOSUPPRESSIVE THERAPY	Aydin Koksal	Received

SAT-286	Cardiac fibrosis and coronary atherosclerosis in cirrhosis. Indications of cirrhotic cardiomyopathy?	Signe Wiese	Received

SAT-287	The role of bile acids in the development of structural myocardial changes and cardiac dysfunction in patients with cirrhosis	Signe Wiese	Received

THU-287	treatment of chronic hepatitis C with direct acting antivirals and its effect on body mass index and hepatic steatosis as measured by controlled attenuation parameter	Hend Shousha	Received

FRI-287	Quantification of hepatitis B virus covalently closed circular DNA by a peptide nucleic acid-clamping PCR method	Chau-Ting Yeh	Received

FRI-288	Long-term outcome of hepatitis delta compared to HBV monoinfection	Anika Wranke	Received

SAT-288	Hepatopulmonary syndrome: a spontaneously reversible condition? Variability in prevalence in a prospective follow-up study of cirrhotic patients	Aurelia Chiricuta	Received

THU-288	factors associated with nonresponse in a cohort of 10655 chronic hepatitis C patients treated with direct acting antivirals	Hend Shousha	Received

SAT-289	Is obesity an additional negative factor in sarcopenic cirrhotic patients?	Daria D´ambrosio	Received

THU-289	Incidence and outcome of portal vein thrombosis in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3-year study	Elisabetta Degasperi	Received

FRI-289	The WHO guidelines for chronic hepatitis B fails to detect half of the patients in need of treatment	Hanna Aberra	Received

THU-290	DIAGNOSIS AND TREATMENT OF HEPATITIS C VIRUS IN A SPANISH JAIL	Juan José Urquijo	Received

SAT-290	Liver cirrhosis and wound healing: Activation of von Willebrand factor and platelets	Lasse Langholm	Received

FRI-290	A new utility of HBcrAg - a pan-genotypic predictor of mother to child HBV transmission	Ivana Carey	Received

SAT-291	The incidence of ulcer bleeding post endoscopic band ligation of esophageal varices	Salvador Machlab	Received

FRI-291	Virological heterogenity of hepatitis delta among Vietnamese populations	Thanh Binh Mai	Received

THU-292	Sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC): a systematic review and meta-analysis	Fanpu Ji	Received

SAT-292	Association between hospital type and transplant-free survival in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunts (TIPS): A population-based study.	Jeffrey Mah	Received

FRI-293	Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection	Arianna Battisti	Received

THU-293	Management of patients with chronic kidney disease in the setting of interferon-free treatment for chronic HCV hepatitis	ELENA LAURA ILIESCU	Received

SAT-293	A simple patient-reported instrument can predict development of overt hepatic encephalopathy	Mette Munk Lauridsen	Received

THU-294	Untreated HCV in HIV/HCV co-infection; data from the TRIO network.	Dushyantha Jayaweera	Received

FRI-294	Patients with genotype 5 hepatitis delta infection have a favourable outcome of disease and better treatment response to pegylated interferon therapy compared to genotype 1 patients	Michelle Spaan	Received

SAT-294	The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention	Mette Munk Lauridsen	Received

SAT-295	Transjugular Intrahepatic Portosystemic Shunt Versus Beta-blocker and/or Endotherapy for Prevention of Variceal Rebleeding in adults with EHPVO	Guohong Han	Received

THU-295	Changing landscape of HCV treatment in Germany: Data from a large real-world cohort 2014-2017	Jörg Petersen	Received

THU-296	Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis	Fred Poordad	Received

FRI-296	Clinical Features of HDV Infection in Mongolian Patients	Anir Enkhbat	Received

THU-297	Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy	Velia Chiara Di Maio	Received

SAT-297	A prospective evaluation of symptom burden,opioid risk in cirrhosis patients	Mina Niazi	Received

FRI-297	Monitoring of subjects with previous Hepatitis B exposure on Rituximab for Hepatitis B reactivation and on demand treatment for Hepatitis B reactivation is safe and reduces cost	Victoria Ekstrom	Received

THU-298	Impact of direct acting antiviral treatment in hospital admission rates in patiens with cirrhosis and hepatitis C virus (HCV) infection.	Álvaro Hidalgo Romero	Received

SAT-298	Critical flicker frequency improves its diagnostic and predictive accuracy of hepatic encephalopathy by decreasing the dispersion between measures.	Javier Ampuero	Received

THU-299	A national study of risk for non-liver cancer in people with hepatitis C treated with direct acting antivirals or an interferon-based regimen	Charlotte Lybeck	Received

SAT-299	Four years outcomes of Baveno VI low risk cirrhotic patients	Priscila Pollo-Flores	Received

SAT-300	A novel sonographic parameter for the quantification of muscle mass in cirrhosis	Kazufumi Kobayashi	Received

FRI-300	Disease progression is affected by pattern of serum alanine aminotransferase (ALT) dynamics in a cohort of patients with hepatitis B e antigen (HBeAg)-negative chronic infection: 4 years follow-up of a prospective longitudinal study (ALBATROS Study)	Viola Knop	Received

SAT-301	Repeated episodes of acute kidney injury (AKI) on the transplant waiting list: Impact on post-liver transplantation renal and patient outcomes	Shuetfong Neong	Received

FRI-301	Serum Mac-2-binding protein glycosylation isomer in assessing liver fibrosis in chronic hepatitis B infection	lung-yi mak	Received

THU-302	Outcomes of direct-acting antiviral therapy for chronic hepatitis C following unrestricted access in Australia: Real-world outcomes from the state of South Australia	James Haridy	Received

FRI-302	Changes in serum levels of the novel mac-2 binding protein glycosylation isomer (M2BPGi) and risk of hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients treated with nucleos(t)ide analogues (NAs)	Yao-Chun Hsu	Received

FRI-303	A risk score combining quantitative hepatitis B surface antigen and core-related antigen levels to predict off-therapy relapse after cessation of nucleos(t)ide analogues in patients with chronic hepatitis B	Yao-Chun Hsu	Received

THU-303	Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: a single-center experience	Roberta D´Ambrosio	Received

SAT-303	Gender differences regarding sarcopenia development in chronic liver disease	Atsushi Hiraoka	Received

THU-304	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study	Chen-Hua Liu	Received

SAT-304	Assessment of subclinical hepatic encephalopathy by using EncephalApp Stroop test and brain MRI	Ioan-Cristian Lupescu	Received

FRI-304	Acute hepatitis B in adulthood: not such a benign disease.	Mar Riveiro-Barciela	Received

FRI-305	The first results of genotyping of virus hepatitis D and virus hepatitis B in Kazakhstan	Bibigul Ilyassova	Received

THU-305	"How do you feel about your diagnosis of Hepatitis C today?" The emotional benefits of direct-acting antiviral therapy.	Sarah Montague	Received

SAT-305	Impact of antibiotic prophylaxis of spontaneous bacterial peritonitis on colonization and infections with multidrug-resistant bacteria	Marcus Mücke	Received

THU-306	Rapid virological response, as a predictor of sustained virological response of Sofosbuvir and Ribavirin in Korean patients with genotype 2 chronic hepatitis C virus infection	Hyun Young Woo	Received

FRI-306	The levels of cytokines in progression of chronic hepatitis D	Bibigul Ilyassova	Received

SAT-306	The Indication, Dosage and Duration of Proton Pump Inhibitors in Liver Cirrhosis	Marianne De Roza	Received

FRI-307	Assessment of Hospitalizations and Comorbidities in 2138 Hepatitis B Patients Followed in Diverse Specialist Care Clinics Based on Administrative Data Analysis. The Canadian Hepatitis B Network.	Carla Coffin	Received

SAT-307	the effect of new infection control measures for the prevention of hospital acquired infections in cirrhotic patients	Vincenza Di Gregorio	Received

THU-307	Ledipasvir 90mg/sofosbuvir 400mg for treatment of children with CHC genotype 4: Single Centre experience.	Gamal Sheha	Received

FRI-308	Can pre-core region mutations distinguish between HBeAg negative genotype A1 and A2 patients with similar HBV DNA viral load levels?	Natalie Bolton	Received

SAT-308	Presepsin, C reactive protein and procalcitonin have similar accuracy for bacterial infection and sepsis in decompensated cirrhosis	Fischer Petra	Received

THU-308	Safety and effectiveness of DAA treatment and clinical outcomes of HCV liver transplanted patients with recurrent hepatitis C infection: a single center 3-year study from Italy	Federica Invernizzi	Received

THU-309	Efficacy and safety of IFN-free DAA therapy in HIV/HCV co-infected patients: Results from a pan-European study	Lars Peters	Received

FRI-309	switching immunoglobulin base therapy to nucleoside/nucleotide analogoes monothearpy is safe&effective as preventive therapy of reccurent HBV in liver transplanted patients- single centre experience	orly sneh	Received

SAT-309	Predictive factors of esophageal varices recurrence after prophylactic endoscopic band ligation	Jaime Rodrigues	Received

SAT-310	A study evaluating outcomes of cirrhotic patients managed in a dedicated liver cirrhosis clinic and factors influencing survival.	David Kockerling	Received

THU-310	EMERGENCE OF HEPATITIS C VIRUS RESISTANCE-ASSOCIATED VARIANTS IN PATIENTS FAILING DIRECT-ACTING ANTIVIRALS BY ULTRA-DEEP SEQUENCING	THUY NGUYEN	Received

SAT-311	Frialty is an independent predictive factor of hospital admissions and falls in patients with cirrhosis	Eva Roman	Received

THU-312	Identification of novel resistance associated substitutions for sofosbuvir in HCV genotype 3a	David Smith	Received

SAT-312	Cardiac assessment in children with chronic liver disease: cholestatic and non-cholestatic	Tawhida Yassin Abdel Ghaffar	Received

THU-313	Utilization and outcomes of elbasvir/grazoprevir in genotype 1B Chronic Hepatitis C: updated retrospective data analyses from the Trio network.	Naoky Tsai	Received

SAT-313	Non-invasive predictors of varices in non-cirrhotic portal hypertension	Morven Cunningham	Received

FRI-313	Validation of AASLD Treatment Guideline Eligibility Based on Disease Outcomes of Large Community and Clinical Cohorts of Chronic Hepatitis B (CHB) Patients	Dong Hyun Lee	Received

SAT-314	Impact of adrenal dysfunction on psoas muscle thickness assessed by computed tomography in patients with liver cirrhosis	Graziella Privitera	Received

FRI-314	Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B	Yun Bin Lee	Received

THU-315	Efficacy, safety and clinical outcomes of Paritaprevir/Ombitasvir/r + Dasabuvir 8 weeks (3D8): results from a spanish real world cohort (Hepa-C)	Marc Puigvehí	Received

FRI-315	Quantitative Hepatitis B surface antigen in different phases of Vietnamese chronic HBV infected patients	Huong Nguyen	Received

SAT-316	Endoscopic radiofrequency ablation for the treatment of gastric antral vascular ectasia in cirrhotic patients: a bi-centric clinical and economical cost-effective analysis	Marco Senzolo	Received

THU-316	Multidisciplinary Support Program for patients with addictions and suspected chronic hepatitis C (MSP ADIC-C) to improve their evaluation and access to antiviral treatment	Marc Puigvehí	Received

FRI-316	HBeAg Negative Chronic Hepatitis B Patients with HBV-DNA Levels Between 2000-20000 IU/ml and Normal Aminotransferases are Really Inactive?	Bilal Ergül	Received

FRI-317	Which pregnancy biomarkers predict post-delivery ALT flares in mothers with chronic hepatitis B?	Salome Imbert	Received

THU-318	Direct acting antiviral treatment improves hepatitis C-related neurocognitive impaiment	Joaquin Cabezas Gonzalez	Received

FRI-318	Adherence to AASLD Treatment Guidelines on Treatment Initiation Among Treatment-Eligible Patients with Chronic Hepatitis B: Experiences from Primary Care and Referral Practices	Vy Hoang Nguyen	Received

FRI-319	Durability of HBsAg loss during or after antiviral Treatment in a predominantly middle european collective	Gerlinde Teuber	Received

THU-319	Effectiveness of 8 vs. 12 week ledipasvir-sofosbuvir (LDV/SOF) in black, treatment naïve patients with non-cirrhotic, genotype 1 HCV and baseline viral load	Michael Curry	Received

SAT-320	Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity	Hiroaki Takaya	Received

FRI-320	The effect of PEG-IFN add on or switch to on HBsAg clearance in HBeAg- CHB patients recieving entecavir treatment	Lei Yan	Received

THU-320	Effectiveness of elbasvir/grazoprevir in patients with cirrhotic genotype 1 or 4 Chronic Hepatitis C: updated retrospective data analyses from the Trio network.	Michael Curry	Received

FRI-321	A virological response to PEG-IFNa treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study	Anika Wranke	Received

FRI-322	Novel markers predict HBs-antigen seroclearance in chronic hepatitis B patients from the SWAP clinical trial	Wah Wah Phyo	Received

THU-322	High efficacy of IFN-free DAA therapy for acute HCV infection in HIV patients	David Chromy	Received

FRI-323	Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy in HDV patients: A phase 2 LOWR HDV-3 study	Harel Dahari	Received

FRI-324	Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection	Harel Dahari	Received

SAT-325	High Mortality Rate in HBV-related Cirrhosis Patients with HEV Superinfection	Tai-Chung Tseng	Received

FRI-326	Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV / HDV co-infection: 18 month follow-up results from the REP 301-LTF study.	Andrew Vaillant	Received

THU-326	HCV treatment responses among people who use drugs (PWUD): an evaluation of patients on and off opiate agonist therapy (OAT) in a real-life setting	Julie Holeksa	Received

SAT-326	Clinical features and outcomes of hepatitis E in patients with underlying chronic liver disease: a respective case-control study	Yijin Wang	Received

SAT-327	Risk factors of hepatitis E related liver failure: a restrospective case-control study	Yijin Wang	Received

THU-327	VIEKIRA PAK (ritonavir-boosted paritavir/ombitasvir and dasabuvir) associated drug-induced interstitial lung disease: Case series with systematic review	YU JUN WONG	Received

THU-328	HCV Genetic Diversity by Geographic Region within Genotype 1-6 Subtypes among Patients Treated with Glecaprevir and Pibrentasvir	Gretja Schnell	Received

SAT-328	The role of hepatitis E in acute non-traumatic neuropathy in China: a prospective case-control study	Yijin Wang	Received

FRI-328	Every-two-week ropegienterferon alfa-2b is safe with higher hepatitis B e antigen seroconversion rate in interferon naive patients with chronic hepatitis B infection: A phase 2, open label, randomized, active control, dose finding study	Yi-Wen Huang	Received

FRI-329	HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B	Mina Farag	Received

SAT-329	Clinical impact, morbidity and mortality of Hepatitis E at tertiary referral centres in central Europe	Johannes Hartl	Received

THU-329	Is treatment of hepatitis C with controlled generic direct acting antiviral drugs effective? An Egyptian experience	Mahmoud Elzalabany	Received

SAT-330	Dynamics of HBsAg clearance in a UK cohort of chronic HBV infection	Philippa Matthews	Received

FRI-330	Determination of the optimum timing of the start of nucleoside analogue by FIB-4 index for hepatitis B patients from the viewpoint of suppressing hepatocarcinogenesis	Shuhei Hige	Received

THU-330	Real-life experience of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin for treatment of HCV-GT4 in Egyptian patients with severe renal impairment	Heba Omar	Received

FRI-331	Treatment of chronic hepatitis B and renal impairment in patients with and without cirrhosis	Vinh Vu	Received

SAT-331	Blood products as source of HEV transmission? 1-year experience with routine HEV screening at a tertiary center	Thomas Horvatits	Received

THU-331	The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is similar in patients who failed interferon-based treatment with first generation protease inhibitors	Ewa Janczewska	Received

THU-332	Characteristicsand retreatment of HCV DAA failure patients: Real-life experience	Isaac Ruiz	Received

SAT-332	Poor outcome of acute hepatitis E in liver cirrhosis and transplant recipients	Mar Riveiro Barciela	Received

FRI-332	Is renal impairment associated with chronic hepatitis B - a propensity score matched study of healthy non-hepatitis B patients compared to patients with untreated chronic hepatitis B	Vinh Vu	Received

FRI-333	Comparison of fibrosis-adjusted long-term clinical outcomes in patients with minimally active chronic hepatitis B who did not undergo antiviral therapy vs. those with complete virological response by antiviral therapy	Hye Won LEE	Received

SAT-333	Preceding Hepatitis E Virus Infection in Patients with Myasthenia Gravis	Lin Wang	Received

SAT-334	Hepatitis A affecting men having sex with men: ongoing outbreak in Israel, December 2016- September 2017	Orna Mor	Received

THU-334	UNEXPECTED FINDINGS FROM A LARGE ASIAN HCV REAL LIFE STUDY	Seng Gee Lim	Received

SAT-335	Incidence of hepatitis E infection in renal transplant patients in The Netherlands	Robin Erken	Received

THU-335	A comparison of elbasvir/grazoprevir, ledispasvir/sofosbuvir and velpatisvir/sofosbuvir therapy among people who use drugs (PWUD): real world experience	Arshia Alimohammadi	Received

FRI-335	Loss of HbsAg is enough to discontinue long-term therapy with Nucleos(T)ide analogues in HbeAg negative CHB patients in real clinical practice?	Andreas Kapatais	Received

THU-337	Safety and effectiveness comparing generic and original sofosbuvir-based treatment regimens in patients with hepatitis C: A prospective multicenter study from Argentina	Ezequiel Ridruejo	Received

THU-338	Integrated efficacy and safety of glecaprevir/pibrentasvir in patients with psychiatric disorders	David BACK	Received

FRI-339	Clinical and virological predictors of response after antiviral therapy interruption in HBeAg-negative chronic hepatitits B	Sabela Lens	Received

THU-339	Real world effectiveness of Ledipasvir/Sofosbuvir based regimens in hepatitis C virus genotype 1,2 and 3 infection within national hepatitis C elimination program in the country of Georgia	Tengiz Tsertsvadze	Received

SAT-339	Longitudinal analysis of HCV full genomes in patients failing NS5A inhibitors reveals the selection of novel amino acid substitutions outside NS5A	Slim Fourati	Received

THU-340	Effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection: real-world data from Georgian hepatitis C elimination program	Tengiz Tsertsvadze	Received

FRI-341	Association of metabolic adipokines with persistence of fibrosis in chronic hepatitis B during long-term nucleoside analogue therapy	Ka-Shing Cheung	Received

FRI-342	Tenofovir Disoproxil Fumarate use during Pregnancy and Infant Bone Health and Growth: the Tenofovir in Pregnancy (TiP) Study	Athena Kourtis	Received

SAT-343	DEAD-box helicases DDX5 and DDX17 areinvolved in the fine tuning of hepatitis B virus minichromosome transcriptional regulation	Fleur CHAPUS	Received

FRI-343	Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a	Andrew Vaillant	Received

SAT-344	Rolling circle amplification and nanopore-based deep sequencing of full-length HBV genomes	Philippa Matthews	Received

THU-344	Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in HIV-negative cancer patients with chronic hepatitis C	Haley Pritchard	Received

FRI-344	A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 240	Jing-Hang Xu	Received

THU-345	The real-world safety and efficacy of sofosbuvir plus ribavirin for eldery patients over 75 years of age	Hideyuki Tamai	Received

SAT-345	LTPprodrug technology offers new generation nucleotide antiviral agents	Lin Zhi	Received

FRI-345	Sustained virological suppression and improved renal function with reduced dose tenofovir disoproxil fumarate in renally compromised patients with chronic hepatitis B	Seng Liem	Received

FRI-346	Low serum HBsAg and HBV DNA predict response of peg-interferon addition to entecavir in HBeAg positive chronic hepatitis B	Seng Liem	Received

SAT-346	Conservation and variation of the hepatitis E virus open reading frame 2 proteome	Shaoshi Zhang	Received

THU-346	Sustained virologic response rates (SVR-12) for chronic hepatitis C genotype 6 patients treated with Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir	Sam Trinh	Received

THU-347	Clinical and virological characteristics of DAA-experienced patients with chronic HCV infection treated with sofosbuvir/velpatasvir/voxilaprevir: results from the Frankfurt Resistance Database	Johannes Vermehren	Received

SAT-347	Mutations in HCV NS3 but no Sec14L2 variants alter HCV RNA replication of natural occuring viruses in cell culture	Sandra Ciesek	Received

FRI-347	Renal outcomes in chronic hepatitis b patients treated with tenofovir disoproxil fumarate or entecavir: a propensity score matched study	Sam Trinh	Received

FRI-348	Peginterferon is superior to nucleos(t)ide analogues for reduction ofchronic hepatitis B-related hepatocellular carcinoma in patients with high-riskscore	Peipei Ren	Received

THU-348	Are patients treated with direct antiviral agents for HCV infection at greater risk for extrahepatic malignancies?	Tarek Saadi	Received

SAT-348	Expanding the donor pool- decontamination of HCV RNA positive kidneys with methylene blue	Sandra Ciesek	Received

THU-349	Real world adherence to Direct-Acting Antivirals in a cohort of drug users in Rome, Italy.	Elisabetta Teti	Received

SAT-349	Seeking genetic determinants of resistance to hepatitis C virus infection in a highly resistant cohort	Daniel Felmlee	Received

FRI-349	Validation of the EASL 2017 HBV clinical practice guidelines criteria for switching patients long-term treated with Tenofovir difumarate to Entecavir or Tenofovir alafenamide in a real life setting	Alessandro Loglio	Received

FRI-350	The long-term risk and outcome of non-neoplastic portal vein thrombosis developing in compesated caucasian HBV cirrhotics treated with Tenofovir or Entecavir	Alessandro Loglio	Received

SAT-350	A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro	Lorenzo Piermatteo	Received

SAT-351	Palmitoylation Determines the Subcellular Localization of the Hepatitis E Virus ORF3 Protein	Jérôme Gouttenoire	Received

FRI-351	Clinical and genetic predictors of HCC occuring in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years	Alessandro Loglio	Received

THU-351	Adverse reactions of Direct-acting AntiviralAgents (DAAs) in HCV patients: our experience	Diana Padovani	Received

FRI-352	Pharmacokinetic-Pharmacodynamic Modeling of Tenofovir Exalidex in HBV Subjects	Robert Foster	Received

THU-352	A Comparison of renal function before and after treatment in chronic hepatitis C patients who achieved sustained viral response with direct acting antivirals	Paul Fitzmorris	Received

THU-353	Fast-track HCV check-up enhances possibility of sustained virologicalresponse in HCV infected patients	Teresa Antonini	Received

THU-354	Grazoprevir/elbasvir dosing according to viral load and NS5A resistance: real world confirmation of the efficacy of EASL guidance	Fiona Marra	Received

SAT-354	Compare HBsAg retention in the endoplasmic reticulum (ER) and the ER stress between the cells transfected or infected by the wild type and pre-S HBV mutants using in vitro transfection and in vivo infection of FRG mice	Jenny Yuh-Jin Liang	Received

FRI-354	HeberNasvac: Novel Therapeutic Vaccine Against Chronic Hepatitis B	Gerardo Guillen	Received

THU-355	Impact of HCV viral load on elbasvir/grazoprevir effectiveness in Chronic Hepatitis C: updated retrospective data analyses from the Trio network.	Steven Flamm	Received

FRI-355	At least 90% long-term adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir	Young-Suk Lim	Received

SAT-355	HBV Peptide Array Demonstrates Candidate Mechanisms of CRV431 Anti-HBV Activity	Robert Foster	Received

SAT-356	Assessing the in vitro anti-HBV activity of combinations including CRV431, TXL, and prototype capsid assembly modulators	Robert Foster	Received

THU-356	Therapeutic Drug Monitoring of DAAs overcomes contra-indications against anti-epileptics in HCV treatment (HepNed003)	minou van seyen	Received

FRI-357	Serum hepatitis B virus DNA and pregenomic RNA levels and kinetics in nucleos(t)ide analogue treated and untreated subjects	Emily Butler	Received

SAT-357	Establishment of a method to compare antiviral effect of drug products by human hepatitis B virus infected humanized chimeric mice	Hatsune Enomoto	Received

THU-357	What impact do the new direct acting antiviral drugs have on the patients quality of life?	Marta Gentili	Received

THU-358	Significant changes of HCV patient characteristics over time in the era of direct antiviral agent (DAA) therapy - are all HCV subpopulations treated similarly? - Results from the GErman hepatitis C COhort (GECCO)	Stefan Christensen	Received

FRI-359	Hepatitis B surface antigen reduction by switching from long-term preceding nucleoside/nucleotide analog administration to pegylated interferon or tenofovir	Tamaki Nobuharu	Received

THU-359	National Quality Control and Validation of Hepatitis C NS3, NS5A and NS5B Genotypic Resistance Testing	Valeria Cento	Received

FRI-361	Virological response and safety in a cohort of immigrant patients affected by chronic hepatitis delta treated with PEG-IFN	Lucio Boglione	Received

SAT-361	HBV reactivation and changes in interferon-stimulated gene expression during treatment of direct-acting antivirals for HCV: Analyses in a novel in vitro model for HBV-HCV coinfection using human induced pluripotent stem cell–derived hepatic cells	Yasuhiro Asahina	Received

FRI-362	RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV	Man-Fung Yuen	Received

THU-363	Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1-6 infection	Marcello Persico	Received

SAT-363	Statin inhibits HDV assembly, secretion, and large hepatitis delta antigen-Smad3-Twist mediated epithelial-mesenchymal transition	Jaw-Ching Wu	Received

FRI-363	Comparison of event-free survival between DAA and IFN-based antiviral therapy for HCV, adjusted for disease severity	Lisette Krassenburg	Received

FRI-364	The number needed to treat to prevent one clinical event at 2 years after antiviral treatment for HCV with DAAs compared to IFN-based therapy	Lisette Krassenburg	Received

SAT-364	Murine hepatocytes with humanized sodium taurocholat polypeptide (NTCP) limit HDV infection in vivo independent of adaptive immune responses	Marc Luetgehmann	Received

THU-364	Multicenter study on outcome of HCV elimination using LDV/SOF combination in Mongolians	Lkhaasuren Nemekhbaatar	Received

FRI-365	TLL1 variants do not predict the development of de-novo hepatocellular carcinoma in HCV cirrhotics treated with IFN-free DAA-based regimens	Pietro LAMPERTICO	Received

SAT-365	Antiviral properties and liver specific delivery of a TLR1/2 ligand in HBV-infected in vitro and in vivo models	Julie Lucifora	Received

SAT-366	Inhibition of Hepatitis Virus X protein (HBx) in HBV-Infected Primary Human Hepatocytes leads to the Reappearance of the Smc5/6 Complex	Rudolf Beran	Received

THU-366	Sofosbuvir/Ledipasvir : Efficacy and tolerance in HCV positive patients naïve or pre-treated in Cameroun	serge tchamgoue	Received

SAT-367	FXR is a proviral factor whose binding to HBV genome is modulated by FXR agonist and correlates with presence of the activated chromatin mark H3K4me3 in an HBx dependant manner	Benoît Lacombe	Received

THU-367	Hepatitis B virus reactivation during direct-acting antiviral therapy in hepatitis B/C co-infected patients on hemodialysis	Chunhua Hu	Received

THU-368	High efficacy of resistance guided retreatment of Genotype 3 in real life	Federico Garcia Garcia	Received

FRI-368	Long-term immunological and clinical impact of HCV eradication with direct acting antivirals (DAAs) in patients with HCV-associated cryoglobulinemia vasculitis	Martin Bonacci	Received

FRI-369	Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a sinlge-center prospective 3 year study	Roberta D´Ambrosio	Received

SAT-369	Reduction of serum infectivity of Hepatitis Delta virus-infected patients treated with Myrcludex B: An in vitro assay to determine infectious units	Katrin Schöneweis	Received

FRI-370	The Impact of HCV Eradication by IFN-free Regimens on the Transition of Precancerous Hepatic Nodules to HCC: a Prospective Observational Study	Hidenori Toyoda	Received

SAT-370	The protein complex structural maintenance of chromosomes reappears after interferon alpha treatment in hepatitis B virus infected humanized mice but its presence does not hinder viral rebound	Maura Dandri	Received

FRI-371	Impact of curative HCC history on the Development of HCC after the Eradication of HCV by DAA Therapy in Patients with HCV Infection	Hidenori Toyoda	Received

SAT-371	Hepatitis B virus escapes non-canonical CTL effector function	Dirk Wohlleber	Received

THU-371	Real world experience with twelve weeks of therapy without ribavirin in genotype 1 HCV infected compensated cirrhotics	Dorota Zarebska-Michaluk	Received

FRI-372	Impact of Direct-acting Antiviral Agents (DAAs) on Liver Function in Patients with Chronic Hepatitis C Virus (HCV) Infection	Hidenori Toyoda	Received

THU-372	Sofosbuvir-based treatment of viral hepatitis C genotype 3 infection - a Polish real-world study.	Dorota Zarebska-Michaluk	Received

SAT-372	HBsAg transcomplementation of defective HBV genomes in HBeAg negative chronic HBV infected patients	Kai-Henrik Peiffer	Received

FRI-373	Sustainable Improvement of Patient-Reported Outcomes (PROs) in Cirrhotic Patients with Hepatitis C (HCV) who Achieved Sustained Virologic Response (SVR)	Zobair Younossi	Received

SAT-373	Recapitulation of the complete HDV replication cycle in a novel hepatoma cell line allows for efficient antiviral compound evaluation	Florian Lempp	Received

THU-373	Naturally occurring drug resitance substitutions in the NS5A and NS5B regions in Hepatitis C virus genotype 2 and response to sofosbuvir plus ribavirin therapy	Kazuhiko Hayashi	Received

FRI-374	The Impact of Sustained Virologic Response on Severe Fatigue in Patients with Chronic Hepatitis C: The Role of HCV Viremia and Co-Morbidities	Zobair Younossi	Received

SAT-374	Proteomic analysis of hepatitis B virus cccDNA-specific associated proteins identifies crucial regulators of viral transcription and RNA processing	Barbara Testoni	Received

THU-374	Effectiveness and safety of direct-acting antiviral therapies in chronic hepatitis C infections patients with cirrhosis in Turkey	Fehmi Tabak	Received

SAT-375	Biogenesis and Function of Intracellular Hepatitis B e Antigen	Bidisha Mitra	Received

FRI-375	DE NOVO HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CIRRHOSIS DUE HEPATITIS C VIRUS INFECTION AFTER TREATMENT WITH DIRECT ANTIVIRAL AGENTS.	Pablo Ruiz	Received

FRI-376	Resolution of clinically significant portal hypertension after sustained virologic response to interferon-free regimens prevents hepatic decompensation	Mattias Mandorfer	Received

FRI-377	Long-term changes of liver elasticity in HVC-infected patients with SVR after treatment with direct-acting antivirals	Veronika Pietsch	Received

THU-377	Real-life efficacy and safety of daclatasvir and asunaprevir therapy for genotype 1b chronic hepatitis C patients without NS5A resistance-associated substitution: A nationwide study in South Korea	Sook-Hyang Jeong	Received

SAT-377	Hepatitis E virus activates signal transducer and activator of transcription 3 to facilitate virus replication	Wenshi Wang	Received

SAT-378	Pro-fibrogenic mediator Osteopontin is intimately involved in Chronic Hepatitis B and promotes cccDNA production	Sandra Phillips	Received

FRI-378	Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma in SVR achieved hepatitis C patients with interferon-free treatment	Yutaka Yasui	Received

THU-378	Genotype 3 Infection in HIV/HCV co-infected subjects in the DAA era: real life data from the ICONA/HepaICONA Foundation cohorts.	Roberto Rossotti	Received

THU-379	Safety and Efficacy of Daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: data from the ICONA/HepaICONA Foundation cohorts.	Roberto Rossotti	Received

FRI-379	LACK OF REDUCTION OF SERUM ALPHAFETOPROTEIN DURING TREATMENT WITH DIRECT ANTIVIRAL AGENTS PREDICTS HEPATOCELLULAR CARCINOMA DEVELOPMENT IN A LARGE COHORT OF PATIENTS WITH HCV-RELATED CIRRHOSIS	Chiara Masetti	Received

SAT-380	Control of glycokinase activity by the HCV protein NS5A increases lipogenesis	Olivier DIAZ	Received

THU-380	Cost-effectiveness analysis of baseline testing for resistance-associated polymorphisms to optimise treatment duration in genotype 1 non-cirrhotic treatment-naive patients with chronic hepatitis C virus	Christopher Fawsitt	Received

FRI-380	THE COURSE OF OESOPHAGOGASTRIC VARICES IN PATIENTS WITH CIRRHOSIS AFTER DAA-INDUCED HCV CLEARANCE	Vincenza Calvaruso	Received

SAT-381	Evolution and persistence of resistance-associated substitutions of hepatitis c virus after daclatasvir plus asunaprevir treatment failures	Yechan JEONG	Received

FRI-381	Sustained and Continued Improvement in Hepatic Fibrosis Beyond the First Year Following Hepatitis C Virus Treatment	Robert Wong	Received

SAT-382	FXR agonist GW4064 represses HBV replication in adult but not in young C3H/HeN mice after HBV transduction with rAAV2/8-HBV	Patrice ANDRE	Received

FRI-382	The role of Hepatitis C virus eradication with DAA on insulin resistence regulation	Ilaria Bortoluzzi	Received

THU-382	Resistance analysis of hepatitis C virus NS5A gene in Brazilian patients infected with genotypes 1 and 3 treated with Daclatasvir	Elisabeth Lampe	Received

FRI-383	Therapy with Oral Directly Acting Agents in Hepatitis C Infection is Associated with Reduction in Fibrosis and Increase in Hepatic steatosis.	. Shalimar	Received

THU-383	Variables associated with persistence of elevated ALT after SVR in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry (DHC-R)	Stefan Mauss	Received

SAT-383	Cellular RetinoicAcid-Binding Proteins Regulation of Hepatitis C Virus Infection	Takeshi Saito	Received

THU-384	Time to Viral Suppression Does Not Impact SVR in Patients Treated with Glecaprevir/Pibrentasvir for 8 Weeks	Christoph SARRAZIN	Received

THU-385	Identification, by Cold-PCR, of treatment-resistant HCV mutations in baseline samples of patients treated with DAAs.	Antonio Madejón	Received

SAT-385	Sodium taurocholate cotransporting popypeptide (NTCP) variants modulate HDV entry according to their function as a bile acid transporter but do not influence the antiviral effect of Myrcludex-B	Olympia Anastasiou	Received

FRI-385	In hepatitis C patients with cirrhosis who achieve SVR with treatment, reduction in transient elastography measures does not translate to reduced risk of hepatocellular carcinoma: A prospective cohort study.	Jessica Howell	Received

FRI-386	Risk of de novo hepatocellular carcinoma after DAA treatment within two years following treatment with Ombitasvir/Paritaprevir/ritonavir±Dasabuvir±Ribavirin in the AMBER– real world experience study	Robert Flisiak	Received

THU-386	Persistence and risk of transmission of the hepatitis C virus NS5B S282T substitution in a HIV-positive man who has sex with men	Astrid Newsum	Received

SAT-386	Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein	Laurence COCQUEREL	Received

THU-387	On treatment HCV-RNA evaluation in real-life: still a role in the era of direct acting antiviral agents?	Francesca Ceccherini Silberstein	Received

FRI-387	Antiviral therapy can prevent in HCV infected patients relapse of diffuse large B cell lymphoma	Adriano Pellicelli	Received

FRI-388	Prospective follow up of 80 patients with addictive behaviors and advanced fibrosis after treatment of chronic HCV infection with DAA : a suboptimal management	camille barrault	Received

FRI-389	Predictors of clinical improvement among HCV patients with advanced liver disease treated with DAA: a single center experience.	Chiara Mazzarelli	Received

THU-389	Ethnic Differences in HCV-related HCC (HCV-HCC) Outcomes: Report from the Real-World Evidence by the Asia Pacific Rim Liver Consortium for HCC (REAL-HCC)	Debi Prasad	Received

SAT-389	Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized uPA/SCID mice using an agent-based modeling approach	Harel Dahari	Received

SAT-390	Understanding HDV and HBV dynamics during acute co-infection in humanized uPA/SCID chimeric mice using an agent-based modeling appraoch	Harel Dahari	Received

FRI-390	Sustained virologic response leading to improved long-term metabolic outcomes	Benjamin Emmanuel	Received

THU-390	Changes in the characteristics of hospital admissions due to complications of cirrhosis in the era of direct-acting antivirals (DAAs) against HCV	Miguel Fraile	Received

FRI-391	High virological cure rate and low rate of reinfection in a project to eradicate HCV in people who inject drugs at risk for non-adherence to direct-acting antivirals in Vienna	Michael Gschwantler	Received

THU-391	Validation of a clinical scoring system to predict risk of hepatocellular carcinoma (HCC) in an ethnically diverse cohort of patients with chronic hepatitis C virus (HCV) infection	Mike Tzuhen Wei	Received

SAT-391	Molecular diversity of HDV strains that spread in France: a study of 2224 clinical strains prospectively collected during fifteen years	Athenaïs Gerber	Received

FRI-392	Circulating microparticles and thrombotic risk in patients with HCV-related cirrhosis who underwent DAA treatment	Alberto Zanetto	Received

THU-392	Minimal Monitoring Of Direct-Acting Antiviral Therapy Within A Real World, Urban Population	Sarah Kattakuzhy	Received

SAT-392	Molecular diversity of HBV and HDV amino-acid sequences involved in HDV virion morphogenesis according to HBV and HDV genotypes: study of 1590 clinical strains	Athenaïs Gerber	Received

FRI-393	A cost-effectiveness analysis of shortened direct-acting antiviral treatment for mild chronic hepatitis C virus	Christopher Fawsitt	Received

SAT-394	Prevalence, Pathogenesis and Cross-species Transmission of A Novel Hepatitis E Virus from Bactrian Camels	Lin Wang	Received

SAT-395	Mitochondrial Electron Transport Chain Complex III: a promising antiviral target for hepatitis E virus	Changbo Qu	Received

THU-396	A universal offer of blood borne virus testing substantially increases diagnosis and treatment of hepatitis C in prisons	Stuart Mcpherson	Received

FRI-396	Treatment of HCV infection with DAAs is associatedwith lower HCC recurrence and improved survival after liver transplant	Katharina Willuweit	Received

SAT-396	HCV induced-miR-21 activation triggers lipid accumulation and promotes viral replication	Sophie Clément-Leboube	Received

SAT-397	Hepatitis E virus replication and interferonresponse in human placental-derived cells	Patrick BEHRENDT	Received

FRI-397	Effect of hepatitis C sustained virological response on the endothelial dysfunction and the cardiovascular risk. HepCAR study.	Rocio Munoz hernandez	Received

THU-397	Multifactor risk evaluation in patients who have eradicated HCV infection: an interim analysis in the PITER cohort	Loreta Kondili	Received

FRI-398	The impact of Direct Antiviral Agent Therapy on liver fibrosis in patient with Advanced fibrosis related chronic hepatitis C	Blaise Kutala	Received

SAT-398	Are there different profiles in microRNA expression in HBV/HDV co-infected patients reflecting plasma HBsAg and HBcrAg concentrations?	Ivana Carey	Received

THU-398	DNA methylation and immune cell markers demonstrate associations of accelerated aging with chronic HCV/HIV co-infection and liver fibrosis	Shyamasundaran Kottilil	Received

FRI-399	Effects of direct-acting antiviral treatment of chronic hepatitis C on macrophage activation, liver stiffness, metabolic liver function and portal hypertension in cirrhosis patients	Tea Lund Laursen	Received

SAT-399	Dimerization: A structural feature for the protection of Hepatitis E virus capsid protein against trypsinization	Wenjuan Wei	Received

SAT-400	The correlations between HBV markers in sera and HBVcccDNA for genotypes	matsui takeshi	Received

FRI-400	Involvement of angiotensin II/angiotensin-(1-7) fibrinolytic pathway in improvement of liver fibrosis in chronic hepatitis C patients who had sustained virological response by direct-acting antiviral therapy: a prospective trial	Nicha Teeratorn	Received

FRI-401	The lack of improvement in liver stiffness after SVR in HCV compensated advanced chronic liver disease is associated with the risk of presenting liver related events	Monica Pons Delgado	Received

THU-402	Changes in Serum Neurotransmitters (NTs) are Associated with Changes in Patient Reported Outcomes (PROs) and Neurocognitive Performance (NP) in patients with Hepatitis C Virus (HCV)-Genotype 1 (GT1) who achieved Sustained Virologic Response (SVR)	Zobair Younossi	Received

FRI-402	Health utilities in Spanish chronic hepatitis C patients treated with direct acting antivirals in real life conditions	Regina Juanbeltz	Received

THU-403	Patient-Reported Outcomes in Chronic Hepatitis C: The Impact of Placebo, Active Treatment, and Sustained Viral Eradication	Zobair Younossi	Received

FRI-403	HEPATITIS C VIRUS INFECTION A NEW REVERSIBLE CARDIOVASCULAR RISK FACTOR IN CIRRHOTIC PATIENTS AFTER VIRAL ERADICATION ?	Tudor Cuciureanu	Received

FRI-404	Controlled Attenuation Parameter (CAP) values of Fibroscan® compatible with steatosis in patients with chronic hepatitis C and changes after sustained virological response	Teresa Broquetas	Received

THU-404	Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia	Marianne Martinello	Received

FRI-405	Recurrent viremia after successful hepatitis C virus (HCV) therapy with direct-acting antivirals in a cohort of people who use drugs (PWUD)	Arshia Alimohammadi	Received

THU-405	The Rapid-EC study - a feasibility study of point-of-care testing in community clinics targeted to people who inject drugs in Melbourne, Australia.	Bridget Williams	Received

SAT-406	Depletion of RIPK1 in hepatocytes exacerbates PolyI:C and Murine Hepatitis Virus induced liver damage	Michel SAMSON	Received

FRI-406	Changes in liver steatosis and lipid metabolism accompanied by successful interferon-free DAAs therapy in HCV infected patients; a comprehensive analysis	Naoki Kawagishi	Received

FRI-407	Impact of direct acting antiviral drugs on HCV- related decompensated liver cirrhosis	El-Sayed Tharwa	Received

THU-407	Evaluation of APRI index to identify cirrhosis prior to direct-acting antiviral HCV treatment	Joseph Doyle	Received

SAT-407	A novel chimpanzee adenoviral vectored HBV vaccine, encoding multiple HBV antigens with a shark invariant chain adjuvant, for use in HBV immunotherapy	Senthil Kumar Chinnakannan	Received

THU-408	Hepatitis C treatment success in primary and tertiary care among people with HCV/HIV coinfection	Joseph Doyle	Received

THU-409	REtrieval And Cure of Hepatitis C patients in the Utrecht province in the Netherlands: REACH	Patricia Kracht	Received

SAT-409	Induction of specific CD4+ T cell helper responses following recombinant ChAd3/MVA vaccination against HCV	Ilaria Esposito	Received

FRI-409	Direct Acting Anti-viral treatment for hepatitis C results in a rapid reduction in MRI measures of hepatic microstructure	Robert Scott	Received

THU-410	Preliminary analysis of the Prime Study; a randomized controlled trial comparing the hepatitis C care cascade in primary care vs. tertiary care	Amanda Wade	Received

SAT-410	Induction of liver sinusoidal endothelial cells immune activation by HBeAg during HBV infection	Jia Liu	Received

FRI-410	Clinical consequences of occult HCV infection in a post-liver transplant population	Jeffrey Kahn	Received

THU-411	Strategic Elimination: Efficacy of Hepatitis C treatment in People Who Inject Drugs (PWID) in an urban, underserved clinic in the United States	Christian Ramers	Received

SAT-411	Regulation of antiviral CD8 T cell response by MMP mediated soluble CD100 releasing in HBV infection	Jia Liu	Received

FRI-411	Incidence of de-novo hepatocellular carcinoma after treatment with direct antiviral agents for hepatitis C: a multicenter prospective cohort study from Latin America.	Federico Piñero	Received

FRI-412	Impact of sustained virological response in the use of concomitant drugs in hepatitis C virus infected patients with comorbidities	Elena González-Colominas	Received

THU-412	Among 1945-1965 Birth Cohort Patients with At Least One Additional Hepatitis C Virus (HCV) Risk Factor, One in Eight Were Positive for HCV Antibody: An Underserved Safety-Net Population Experience	Grishma Hirode	Received

FRI-413	Noninvasive diagnosis of fibrosis in the patients with hepatitis C virus infection treated with direct-acting antivirals	Hiroshi Numao	Received

THU-413	Among patients being treated in addiction center, alcohol consumption increases the risk of hepatitis C seroconversion and the severity of hepatic fibrosis in those seropositive for hepatitis C virus.	Michel Doffoël	Received

THU-414	Prevalence and clinical characteristics of portal vein thrombosis in HCV related cirrhosis: a cohort of Egyptian patients	Omar Elshaarawy	Received

SAT-414	Hepatitis B virus entry in primary human hepatocytes initiates toll-like receptor 2-dependent immune signaling.	Ruth Broering	Received

FRI-414	Impact of SVR to IFN-free DAA therapy on steatosis in HIV/HCV coinfected patients	David Chromy	Received

SAT-415	Probing new HBV therapies using fine needle aspirates to sample compartmentalised liver-resident immunity and hepatocytes	Upkar S. Gill	Received

THU-415	Outcomes of an opt-out strategy for Hepatitis C testing in the East Midlands prison estate	Kathryn Jack	Received

FRI-415	Sustained virological response predicts fibrosis regression in chronic hepatitis C patients treated with direct acting antivirals-a single tertiary care centre experience	RAJENDRA GUNJAL	Received

SAT-416	HBV-specific T cell responses in low replicating inactive carrier patients are independent of Hepatitis B surface antigen load	Upkar S. Gill	Received

FRI-416	Long-term evolution of thrombocytopenia in patients with chronic hepatitis C and advanced fibrosis after sustained virological response with direct antiviral agents.	Judith Gómez- Camarero	Received

FRI-417	Treatment of Patients with Decompensated Cirrhosis with DAAs Improves Clinical Symptoms without Affecting their MELD Score.	John Romano	Received

SAT-417	Outcome of anti-viral immunity in the liver is shaped by the level of antigen expressed in infected hepatocytes	Katrin Manske	Received

THU-417	Antiviraltreatment of Hepatitis C improve glucosemetabolism along the entire spectrum from normal glucose tolerance to diabetes.	Sara Bianco	Received

FRI-418	Development of hepatocellular carcinoma following HCV eradication by direct-acting antivirals: Real-life experience from Japanese multicenter cohort	Eiichi Ogawa	Received

SAT-418	The RNA genome of hepatitis E virus robustly triggers antiviral interferon response	Wenshi Wang	Received

SAT-419	The impact of HBsAg on general and HBV-specific immunity	Nina Le Bert	Received

THU-420	Early HCV Viral Kinetics in the Setting of Transplantation of Kidneys from HCV-infected Deceased Donors into HCV-negative Recipients	David Goldberg	Received

SAT-420	Normalization of NK cell phenotype is delayed after successful interferon-free therapy in cirrhotic patients with chronic HCV infection.	Elena Perpiñan	Received

SAT-421	Transcriptome profiling of hepatitis B virus-infected human hepatocyte derived from chimeric mice with humanized liver	Shingo Nakamoto	Received

THU-421	Screening for neurocognitive dysfunction in non-cirrhotic chronic hepatitis C infection in an Irish academic unit.	Damien Ferguson	Received

FRI-421	Prevalence and stratification of NAFLD/NASH in a UK and US cohort using non-invasive multiparametric MRI	Stephen Harrison	Received

THU-422	Decrease in blood borne viral infections, liver fibrosis and drug use in a Danish prison population	Peer Brehm Christensen	Received

THU-423	Strong correlation of hepatitis B virus prevalence among Mongolian adults 40 to 65 years old of age with HCC mortality rate: A result from the national general hepatitis screening program	Uurtsaikh Baatarsuren	Received

FRI-423	Non-invasive liver tests in electronic health records of patients with non-alcoholic fatty liver disease: combined analysis from four European countries	William Alazawi	Received

THU-424	Identification of the fast progression and spontaneous regression liver fibrosis phenotypes by a serological collagen turnover profile	Sara Toftegaard Hjuler	Received

SAT-424	Upregulated innate immune responses in a hepatitis C virus exposed uninfected cohort	Kris Bennett	Received

FRI-424	Algorithm to identify patients with an activity grade > 2 in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD)- development in a large prospective multicenter UK study -	Philip Newsome	Received

THU-425	Field evaluation of Xpert (Cepheid) Hepatitis C Virus assay for RNA quantification in Genotype 6 predominant patient population in Cambodia	Sokchea Yann	Received

FRI-425	Noninvasive mapping of fibrosis and inflammation in nonalcoholic fatty liver disease: isolating fibrogenesis in the Space of Disse with MRI R2 multicomponent relaxometry	Hilton Leao Filho	Received

THU-426	Screening for hepatitis C at the emergency department: babyboomers should also be screened in Belgium.	Rob Bielen	Received

SAT-426	HLA-A2 restricted CD8+ T cell immune hierarchy towards full length Hepatitis E virus (HEV) for T cell-based therapy in chronic HEV.	Chaifen Soon	Received

FRI-427	An algorythm for screening for liver fibrosis in primary care using population-based data	Isabel Graupera	Received

SAT-427	Development and characterization of unique Hepatitis C virus neutralizing antibodies associated with infection outcome	Shiri Elmedvi Baran	Received

THU-427	Factors related to differential HCV therapy success or failure based on clinic location within a single health system: A possible role for increasing access to co-located support services?	Jacqueline Sherbuk	Received

FRI-428	Comparison of ElastPQ Shear-wave Elastography (ElastPQ-SWE) and FibroScan Transient Elastography (F-TE) for liver fibrosis staging in patients with NAFLD.	Davide Roccarina	Received

SAT-428	EP2 associated with the inflammatory storm in HBV related acute-on-chronic liver failure	Yunyun Wang	Received

THU-429	Strong increase of acute HCV infections in HIV-negative men having sex with men	laurent Cotte	Received

FRI-429	Establishing reliability criteria forLiver ElastPQ Shear-wave Elastography (ElastPQ-SWE): comparison between 3, 5and 10 measurements.	Davide Roccarina	Received

SAT-429	Cytokine-Dependent Activation of MAIT Cells by the TLR8 agonist GS-9688 but not the TLR7 Agonist GS-9620	Hassan Javanbakht	Received

SAT-430	Characterization of theHEV-specific CD8+ T-cell response in acute and chronic Hepatitis E virus infection	Janine Kemming	Received

THU-430	Implementation of a Unique Hepatitis C Care Continuum Model in a Resource Limited Setting	Poonam Mathur	Received

FRI-430	Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study	Louise Alferink	Received

THU-431	The IL6 -174 C/C genotype is associated with high quality of life scores in patients with chronic hepatitis C	Luciana Diniz Silva	Received

SAT-431	A pan-genotype HCV T cell vaccine, in a simian adenovirus vector, to target T cell epitopes conserved across multiple HCV genotypes	Timothy Donnison	Received

SAT-432	Performance of recomWell HEV and Wantai HEV in acute Hepatitis E and German blood donors	Friedhelm Struck	Received

SAT-433	Ex vivo characterization of co-inhibitory molecules on MHC class II tetramer positive HCV-specific CD4+ T cells in HCV infection	Christin Ackermann	Received

THU-433	Cost-effectiveness of one-time screening for hepatitis C virus infection in Korean general population	Kyung-ah kim	Received

FRI-433	Electronic-nose breath print distinguishes non-alcoholic fatty liver disease from healthy lean control: a pilot study	Rohit Sinha	Received

THU-434	Case finding can successfully re-engage persons lost to follow-up and increase treatment rates in hepatitis C virus services	lynsey corless	Received

SAT-434	Association of PD1 and TIM3 Polymorphisms with HBV Susceptibility	Chunhong Huang	Received

FRI-434	A study of breath metabolome in Non-alcoholic fatty liver disease	Rohit Sinha	Received

THU-435	Direct acting anti-viral therapy rescues neutrophil dysfunction in hepatitis C infection by reduction of heamolysis	Bettina Leber	Received

FRI-435	Appropriateness of inclusion criteria according to transaminases ALT in studies assessing performances of non-invasive tests in type-2 diabetes patients (T2D)	Thierry Poynard	Received

THU-436	Treatment of Adolescents genotype 4 chronic HCV infected patients with Ledipasvir/Sofosbuvir Combination: a real world experience	Dina Attia	Received

SAT-436	A systematic comparison reveals dynamic differences in early adaptive immune responses of acute-resolving versus chronic HBV replication	Qin Wang	Received

FRI-436	Performance and reliability of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity	Andreas Drolz	Received

FRI-437	Controlled attenuation parameter is useful in the diagnosis of fatty liver disease and allows to identify patients with high vascular risk as well as those with advanced liver disease	Marta González	Received

THU-437	Impact of a hepatitis C virus electronic medical record screening alert for baby boomers	Robyn Teply	Received

FRI-438	Effects of bariatric surgery on Non-alcoholic fatty liver disease: The role of macrophage-mediated the systemic inflammation	Noemí Cabré	Received

FRI-439	Magnetic Resonance Elastography versus Transient Elastography in detection of fibrosis in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participant date	Cynthia Hsu	Received

SAT-441	Alcoholic Liver Disease replaces HCV Infection as the Leading Indication for Liver Transplantation in the United States	Daniel Zaldumbide	Received

FRI-441	Utility and limitation of non-invasivefibrosismarkersfor predicting the prognosis in biopsy-proven Japanese NAFLD patients	Takanori Ito	Received

THU-441	Stk25 Antisense Oligonucleotide Treatment Reverses Glucose Intolerance, Insulin Resistance, and NAFLD in Mice	Margit Mahlapuu	Received

THU-442	Decreased circulating peripheral blood Mucosal Associated Invariant T (MAIT) cells is correlated with insulin resistance in patients with Nonalcoholic fatty liver disease (NAFLD)	Johnny Amer	Received

FRI-442	FibroScan stiffness and CAP in the evaluation of cardiovascular risk assessment in patients with NAFLD	Rosa Lombardi	Received

SAT-442	Individualized prediction of the risk of liver-related death in patients with alcoholic cirrhosis	Marot Astrid	Received

FRI-443	Repeatability and Reproducibility of Multiparametric Magnetic Resonance Imaging of the Liver	Henry Wilman	Received

SAT-443	Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis	Marot Astrid	Received

THU-443	Angiopoietin-2 as therapeutic target for pathological angiogenesis and inflammation in non-alcoholic steatohepatitis	Sander Lefere	Received

THU-444	Lipid-induced ASK1 activation in hepatocytes and Kupffer cells mediates the increased vulnerability of fatty liver to Ischemia/Reperfusion injury in mice	Chiara Imarisio	Received

FRI-444	The Community based management of NAFLD Study (COMMANDS): Improved diagnosis and referral using a novel integrated care pathway	lynsey corless	Received

SAT-445	Prevalence of alcoholic steatosis in the general adult Portuguese population	Jorge Antonio M.Carvalho Pratas Leitao	Received

FRI-445	Enhanced liver fibrosis (ELF) score accurately detects advanced fibrosis in nonalcoholic fatty liver disease (NAFLD).	Rudolf E. Stauber	Received

THU-445	Role of rare pathogenic mutations in the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease	serena pelusi	Received

SAT-446	Making sense of Liver Function tests: Is the Intelligent Liver Function Test (iLFT) cost-effective?	Kathleen Boyd	Received

FRI-446	Genetic variations of three important anti-oxidative enzymes: SOD2, CAT and CPX1 in non-alcoholic steatohepatitis	Yi-Shin Huang	Received

FRI-447	Comparison of conventional ultrasound signs to current state-of-the-art MRI method for detection of hepatic steatosis	Mi Mi Kim	Received

THU-447	Metabolomic patterns associated with known genetic variants for hepatic steatosis and non-alcoholic steatohepatitisidentify biomarkers that may be of utility in predicting adverse liver outcomes	Jake Mann	Received

SAT-448	Higher Early Post-Liver Transplant Mortality in Recipients with Severe Alcoholic Hepatitis Versus Alcoholic Cirrhosis	Brian Lee	Received

THU-448	Gut barrier dysfunction contributes to the pathological progression of nonalcoholic fatty liver disease induced by high fat diet in mice	Jinghua Peng	Received

THU-449	Inhibitionof IL-1 signaling in hepatocytes retains insulin sensitivity and protects fromhepatocellular injury in non-alcoholic fatty liver disease (NAFLD).	Nadine Gehrke	Received

FRI-449	A non-invasive biomarker of hepatic inflammation based on magnetic resonance imaging	Tim St Pierre	Received

SAT-449	Bayesian sparse regression modelling more accurately predicts mortality risk than commonly used prognostic scoring systems in patients with severe alcoholic hepatitis	Stephen Atkinson	Received

FRI-450	Temporal assessment of the non-invasive fibrosis scores FIB-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS) in a retrospective cohort study among patients with Non-Alcoholic Fatty Liver Disease (NAFLD)	Carolina Muñoz Codoceo	Received

THU-450	Mechanism for Hypertriglyceridemia and Effect of Fibrate Coadministration During Acetyl-CoA Carboxylase Inhibitor Treatment	Leigh Goedeke	Received

SAT-450	Insufficient diagnostic accuracy of general practitioners and routine liver function tests lead to high risk of under-referrals of patients with alcohol induced advanced liver fibrosis	Thor Lars Hansen	Received

SAT-451	Delineating Complement Activation Molecular Patterns in Patients with Alcoholic Hepatitis	Rebecca McCullough	Received

FRI-451	In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease	Amalia Gastaldelli	Received

THU-451	Effect of exercise on gut microbiota and metabolic status modulation in an in vivo model of early obesity and NAFLD	Sara Carbajo-Pescador	Received

FRI-452	Excess weight has a major impact on hepatic fibrosis by users of psychoactive substance	Michel Doffoël	Received

THU-452	The paracrine effect of visceraladipose tissue obtained at bariatric surgery on primary human hepatic stellatecells grown in human 3D healthy liver scaffolds	Krista Rombouts	Received

SAT-452	Presence of IgA isotype F-actin is frequent in patients with cirrhosis and consitutes the risk of progressive disease course	Boglárka Balogh	Received

THU-453	Integrative analysis of NGS data highlight a genetic variant in ATG7 gene as a novel risk factor for nonalcoholic fatty liver disease progression.	Guido Alessandro Baselli	Received

SAT-453	The TIM3-Gal9 immune checkpoint axis is inter-linked with severity of Alcoholic Liver Disease.	Antonio Riva	Received

FRI-453	Hepatic microRNA and phosphoproteomic analysis provide insights about hepatic collagen deposition and stage of fibrosis in non-alcoholic steatohepatitis	Zobair Younossi	Received

SAT-454	Interleukin-22 binding protein in alcoholic hepatitis	Sidsel Støy	Received

THU-454	Effect of Combined Farnesoid X Receptor Agonist (INT747) and Dipeptidyl Peptidase-4 Inhibitor (sitagliptin) on Liver Fibrosis.	Naotaka Shimozato	Received

THU-455	Efficacy of statins for the treatment of non-alcoholic steatohepatitis (NASH) with mild portal hypertension	Miren Bravo	Received

FRI-455	Liver and pancreatic steatosis in children are both assosiated with metabolic syndrome but have different influence on insulin sensitivity and glucose metabolism	Olha Lukianenko	Received

SAT-456	Collagen proportionate área is an independent predictor of long term outcome in patients with alcoholic liver disease	Marta Guerrero Misas	Received

SAT-457	Hepatoprotective Biomarkers, Amphiregulin and Soluble Fas, IncreaseDuring ELAD Treatment in Alcoholic Hepatitis Subjects	Jason Lapetoda	Received

THU-457	Nicotine enhances lipid accumulation and lipotoxicity in hepatocytes via suppression of autophagy.	Shunhei Yamashina	Received

FRI-457	Metabolomics in the progression of fatty liver disease	Jacopo Troisi	Received

FRI-458	Comparison of HepaFat-Scan and controlled attenuation parameter for the estimation of hepatic steatosis in patients with non-alcoholic fatty liver disease using histology as the reference standard	Wah-Kheong Chan	Received

THU-458	Involvement of the CREB-E2F2-PPAR axis in non-alcoholic fatty liver disease development and progression to hepatocarcinoma	Patricia Aspichueta	Received

SAT-458	The use of proton pump inhibitors among patients with alcoholic cirrhosis is not related with increased risk of death	Ulrich Bang	Received

SAT-459	miRNA regulation of macrophage M1/M2 polarization of Kupffer cells and PBMCs in alcoholic liver disease	Adam Kim	Received

FRI-459	Measuring what matters to patients: the development of the NASH-CHECK, a new patient-reported outcome instrument for nonalcoholic steatohepatitis	Maria Magdalena Balp	Received

THU-459	Akkermansia spp. mediates protection from obesity-associated NAFLD development in germ free mice following intestinal microbiota transplantation from high fat diet and quercetin treated donors	David Porras	Received

THU-460	Bile acid composition modulate insulin resistance in non-diabetic patients with NAFLD	Chiara Rosso	Received

FRI-460	Spatial systems lipidomics reveals nonalcoholic fatty liver disease heterogeneity.	Klara Scupakova	Received

SAT-460	The correlation of obesity with morbidity and mortality in alcoholic hepatitis.	yasir yasiralazzawi	Received

SAT-461	Serum metabolic profiling for the identification of patients with severe alcoholic hepatitis	adelina horhat	Received

FRI-462	FIBROSpect®NASH Serum Test Identifies Advanced Liver Fibrosis in Patients with NonalcoholicSteatohepatitis: Results of a Validation Study	Rohit Loomba	Received

THU-462	Non-alcoholic steatohepatitis impairs Kupffercell-mediated immune tolerance in the mouse liver	Stéphanie Lacotte	Received

SAT-463	Corticosteroid treatment is associated with a resolution of altered CD4+ T cell phenotype in patients with severe alcoholic hepatitis	Ashwin Dhanda	Received

FRI-464	ELF test in NAFLD: poorconcordance with liver stiffness values	Laura Iogna Prat	Received

THU-464	The vanin 1-cysteamine pathway regulates immune tolerance upon lipid-induced oxidative stress in non-alcoholic fatty liver disease	Olivier Govaere	Received

SAT-465	Masked hemolysis as novel factor contributing to hepatic iron overload in ALD	Vanessa Rausch	Received

THU-465	BAFF neutralization ameliorates the evolution of experimental NASH	Salvatore Sutti	Received

FRI-465	Aetiology and severity of liver disease in HIV positive patients with suspected NAFLD: lessons from a cohort with available liver biopsies	Laura Iogna Prat	Received

THU-466	The multifactorial pathogenesis of nonalcoholic fatty liver disease: connecting inflammation and oxidation	Fedra Luciano-Mateo	Received

SAT-466	Use of rifaximin in alcoholic hepatitis: Pilot study.	Cesar Jimenez	Received

THU-467	Expression of the chemokine CCL24 and its receptor in the sera and livers of patients with non-alcoholic fatty liver disease	Yaakov Maor	Received

FRI-467	A new score to predict presence of advanced fibrosis in NAFLD and comparison with established scoring systems	Hannes Hagström	Received

FRI-468	Evaluation of Severity of Hepatic Fibrosis and Steatosis in Biopsy-proven NAFLD Patients Using MR Imaging, Transient Elastography, and Serum Biomarker	Young-Sun Lee	Received

THU-468	LJN452 (tropifexor) attenuates steatohepatitis, inflammation, and fibrosis in dietary mouse models of nonalcoholic steatohepatitis	Bryan Laffitte	Received

THU-469	EDP-305 modulates lipoprotein metabolism via distinct chromatin and microRNA regulatory mechanisms	Lijuan Jiang	Received

FRI-469	Monocyte subpopulations for non-invasive diagnosis of NAFLD and NASH in a bariatric patient collective	Katharina Staufer	Received

SAT-471	Maternal dietary patterns and the risk of large-for-gestational age births	Satomi Minato	Received

THU-471	Inhibition of IL6 trans-signaling leads to NAFLD, mature-onset obesity and metabolic syndrome	tali lanton	Received

THU-472	Genetic and functional analysis of FGF21 in NAFLD/NASH	Rocío Gallego-Durán	Received

SAT-472	Impact of short term weight loss (very low calorie diet vs bariatric surgery) on hepatic insulin resistance and plasma lipidomic profile	Chiara Barbieri	Received

FRI-472	Positive predictive value of a physician diagnosis of non-alcoholic steatohepatitis is low and risks high rates of unnecessary liver biopsy	Anna Roskilly	Received

FRI-473	Screening for liver fibrosis using transient elastography by fibroscan and fibrotest in type 2 diabetic patient	Julia Sandler	Received

THU-473	Divergent effects of RIP3 and MLKL inhibition on HF diet induced steatosis	Waqar Saeed	Received

FRI-474	Body mass index influences Controlled Attenuation Parameter (CAP) values measured with Fibroscan® M probe. When should we evaluate steatosis with the XL probe?	Teresa Broquetas	Received

THU-474	Micro RNA 199a-3p attenuates hepatic lipogenesis through regulating specific protein 1.	Yang Cheng	Received

THU-475	RIPK1 depletion exacerbates progression of liver fibrosis in high fat diet induced non-alcoholic steatohepatitis (NASH) in mice	Jacques Le Seyec	Received

SAT-475	Prediction of decompensation events in NASH cirrhosis patients	Roberta Forlano	Received

SAT-476	A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease	Roberta Forlano	Received

FRI-476	Feasibility and utility of controlled attenuation parameter and transient elastography in the assessment of nonalcoholic fatty liver disease severity in children	Andrea Scott	Received

FRI-477	Optimal cutoff value of assessing changes in intrahepatic fat amount by using the controlled attenuation parameter in a longitudinal setting	Bo-Kyeong Kang	Received

SAT-477	Lipofuscin is detected in early stages of the disease in liver biopsies of patients with Non-Alcoholic Fatty Liver Disease	Roberta Forlano	Received

THU-477	Clinical-grade human liver mesenchymal stem cells reduce NAS score and fibrosis progression in advanced stage NASH pre-clinical model through immunomodulation	Maria Mercedes Binda	Received

THU-478	Ablation of Interleukin-4 Receptor alpha in macrophages ameliorated steatohepatitis and fibrosis in murine model of non alcoholic steatohepatitis (NASH)	Muhammad Ashfaq-Khan	Received

FRI-478	Saroglitazar Treatment Prevents NASH, Eliminates Hepatocyte Ballooning, and Significantly Improves Serum LFTs, Lipids and and Insulin Resistance in DIAMOND(tm) Mice Compared to Pioglitazone Benchmark	Daniel Zaldumbide	Received

FRI-480	Fibrosis stage improvement in nonalcoholic steatohepatitis: a systematic review of placebo treated participants in randomized controlled trials	Anna Roskilly	Received

THU-480	Evaluation of the rodent Octodon degus as a pre-clinical model of liver fibrosis	Sarah Brockbank	Received

SAT-480	Histological severity is related to cardiovascular events in lean but not in overweight and obese subjects with NAFLD	Alexandra Feldman	Received

FRI-481	Persistent improvement of liver function tests and health-related quality of life from an individualized exercise program in patients with histological confirmed NAFLD - the HELP study	Yvonne Huber	Received

THU-481	Impact of Proprotein Convertase Subtilisin/Kexin Type 7 genetic variation in patients with Non-Alcoholic Fatty Liver Disease	Paola Dongiovanni	Received

SAT-481	Characterization of Patients with Both Alcoholic and Nonalcoholic Fatty Liver Disease (BAFLD) in a Large United States Cohort	Naim Alkhouri	Received

SAT-482	Increased gut permeability is associated with oxidative stress in patients with NAFLD	Francesco Baratta	Received

SAT-483	Increasing Trend forHepatocellular Carcinoma (HCC) Linked to Nonalcoholic Fatty Liver Disease(NAFLD) in the United States	Ethan Miller	Received

THU-483	Discovery of Inhibitors of NLRP3 Inflammasome Assembly for the Treatment of NASH and Liver Fibrosis	Davide Povero	Received

THU-484	Four-and-a-half LIM-Domain Protein (FHL2) affects diet induced (hepatic) steatosis and lipid droplet formation	Judith Sommer	Received

SAT-484	Non-alcoholic fatty liver disease in non-obese young adults	Yaakov Maor	Received

SAT-485	Risk factors for development of severe liver disease in more than 400 000 patients with type 2 diabetes: a population-based cohort study	Karl Björkström	Received

FRI-485	Safety,Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Liver-Targeting ACC Inhibitor (PF-05221304) Following Single and Multiple Oral Doses	Arthur Bergman	Received

THU-485	Hepatic effects of NS-0200 (Leucine-Metformin-Sildenafil) in an obese mouse model of diet-induced and biopsy-confirmed NASH	Michael Zemel	Received

FRI-486	Regular Aspirin Use Is Not Protective Against Advanced Fibrosis in Type-2 Diabetics with Biopsy-Proven Nonalcoholic Fatty Liver Disease	Amandeep Singh	Received

SAT-486	Multidisciplinary intervention on lifestyle improves the management of patients with nonalcoholic fatty liver disease	Sara Policarpo	Received

THU-486	Comorbidity-specific augmented hepatic injury in a murine model of obesity-induced NAFLD and peritoneal sepsis	Paul Horn	Received

THU-487	The anti-inflammatory and anto-fibrogenic effects of namodenoson in NAFLD/NASH animal models	Shira Cohen	Received

SAT-487	Long-term Associations between Non-High Density Lipoprotein Cholesterol and Apolipoprotein B in Young Adulthood and Subclinical Atherosclerosis in Persons with Nonalcoholic Fatty Liver Disease in Middle Age: The CARDIA Study	Lisa VanWagner	Received

SAT-488	Association of Nonalcoholic Fatty Liver Disease with Changes in Left Ventricular Structure and Function: The Coronary Artery Risk Development in Young Adults (CARDIA) Study	Lisa VanWagner	Received

THU-488	Histopathologic assessment of fatty liver progression in a rodent model of chronic intake of high-fat diet, ethanol or both	Carolina Guzman	Received

THU-489	Nicotinamide, not N1 methylnicotinamide, ameliorates hepatic steatosis via NAD-depended sirtuin activation	Shusuke Morizono	Received

SAT-489	Investigating the Relationship Between Rare Genetic Variants and Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease	Julia Wattacheril	Received

FRI-489	Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects	Nathalie Adda	Received

THU-490	Elafibranor and obeticholic acid differentially alter NASH and lipid metabolism in diet-induced NASH mouse and hamster models	Francois Briand	Received

FRI-491	Improvement of liver steatosis achieved byprobiotics in patients with nonalcoholic fatty liver disease	Ionel Copaci	Received

SAT-491	Mixed hepatic iron deposition but not serum ferritin is associated with the presence of nonalcoholic steatohepatitis (NASH)	Elena Buzzetti	Received

SAT-492	NAFLD HAS A NEGLIGIBLE ROLE FOR SURVIVAL IN OLD SUBJECTS	Giampaolo Bianchi	Received

FRI-492	Endoscopic sleeve gastroplasty improves liver enzymes and hepatic steatosis index	Sonal Kumar	Received

THU-492	CD4+ RORgt+ T cells, CD4+ T-bet+ T cells, CD4+ CD25+ Foxp3+ T cells and CD8+ T cells are differentially altered in liver and adipose tissue of mice fed a high-fat high-fructose diet in a time-dependent manner	Mikhail Van Herck	Received

SAT-493	Do patients with abnormal liver tests and nonalcoholic fatty liver disease get statins even when indicated?	Sonal Kumar	Received

FRI-493	Effects of Rosuvastatin and PioglitazoneLong Therapy on NASH and Coronary Heart Disease courses	Nataliya Virstyuk	Received

SAT-494	The effect of microvascular complications of diabetes on advanced fibrosis in nonalcoholic fatty liver disease	Sonal Kumar	Received

FRI-494	Correction of intrahepatic microcirculation disorders by L-ornithine-L-aspartate at the chronic liver diseases patients	Tatiana Ermolova	Received

FRI-495	The anti-fibrotic agent, tipelukast (MN-001) reduces serum triglyceride significantly in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients with hypertriglyceridemia after 4 weeks of treatment, an interim analysis of ongoing clin	Kazuko Matsuda	Received

THU-495	LXR inverse agonists inhibit de novo lipogenesis and reduce intestinal lipid and cholesterol absorption in a NAFLD mouse model	Claus Kremoser	Received

SAT-495	Associations between Sarcopenia and Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in the United States	Karn Wijarnpreecha	Received

SAT-496	The Platelet Count is Declining in American Adults in Parallel with an Increase in Risk Factors for Nonalcoholic Fatty Liver Disease	Amandeep Singh	Received

FRI-496	Lifestyle Intervention is effective in treating non-alcoholic fatty liver disease in morbidly obese patients	Simon Hohenester	Received

THU-496	Maternal obesity programs offspring s liver immune cells intra-uterine	Jude Oben	Received

SAT-497	Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease	Daniel Zaldumbide	Received

THU-497	Elafibranor restores lipogenic gene expression in a human skin stem cell-derived non-alcoholic fatty liver disease (NAFLD) model	Joost Boeckmans	Received

SAT-498	The relationship between NAFLD and breast cancer: High prevalence and poor prognosis.	Young-Sun Lee	Received

THU-498	The interplay between liver and muscle begins much earlier than cirrhosis. A diet-induced animal model	FRANCESCA MARIA TROVATO	Received

THU-499	Hyperreactivity to vasoconstrictors in a rat model of non-alcoholic fatty liver disease	Denise van der Graaff	Received

SAT-499	Impact of duodenal-jejunal bypass liner on non-alcoholic fatty liver disease	Thomas Karlas	Received

FRI-499	s-ademetionine effectively prevents drug-induced liver injury in overweight patients with acute leukemia	Igor Skrypnyk	Received

THU-500	Role of mitofusin-2 in NAFLD and targeting by miRNAs	André Simão	Received

FRI-500	Drug exposure and risk of Acute Liver Failure leading to registration for liver Transplantation (ALFT): Results of the SALT III study in adults in France	Dominique Larrey	Received

SAT-500	Nonalcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes: A prospective cohort study	Won Kim	Received

SAT-501	Plasma cells in non-alcoholic steatohepatitis correlates with disease activity	Mehul Lamba	Received

FRI-501	Long-Term Liver Safety of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia: Three-Year Data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)	Dominique Larrey	Received

SAT-502	Cardiovascular risk factors and fibrosisseverity in NAFLD: is there a link?	Davide Roccarina	Received

FRI-502	Proof-of-concept of full-length genome sequencing as diagnostic tool of acute viral hepatitis	Isaac Ruiz	Received

FRI-503	MH cells in combination with proteomics identify a potential biomarker for Drug-induced Liver Injury by Diclofenac	Daniel Zaldumbide	Received

SAT-503	Prevalence, severity and patterns of clinicalpractice in outpatient visits for suspected NAFLD – the German CONSTANS STUDY	Jörn Schattenberg	Received

FRI-504	Health care utilisation in spontaneous survivors of acute liver failure.	Mhairi Donnelly	Received

SAT-504	Analyze of ballooning biomarker in patients with non-alcoholic steatohepatitis: A multicenter study.	Yuji Ogawa	Received

THU-504	The changing profile of extracellular vesicles in non-alcoholic fatty liver disease progression and their role in signalling to hepatocytes	Linda Ban	Received

THU-505	RIP3-dependent signalling contributes to non-alcoholic fatty liver disease-related hepatocarcinogenesis	Marta B. Afonso	Received

FRI-505	Amatoxin poisoning in Germany – important clues for clinical practice	Bernhard Schlevogt	Received

SAT-505	Health-related quality of life correlates with histological severity in non-alcoholic fatty liver disease	Yvonne Huber	Received

THU-506	NAFLD in HIV Mono-infection is a consequence of insulin resistance but not bacterial translocation.	James Maurice	Received

FRI-506	Opal, but not MARS improves patients albumin binding function measured by Electron Spin Resonance (ESR) in a prospective multicenter trial	Daniel Zaldumbide	Received

SAT-506	Influence of non-alcoholic fatty liver disease on cardiovascular risk in patients with stable coronary heart disease	Iryna Vakalyuk	Received

SAT-507	Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity	Javier Ampuero	Received

THU-507	Hepatic steatosis potentiates irinotecan-induced hepatocellular injury via dysregulation of irinotecan-metabolizing enzymes	Abdo Mahli	Received

THU-508	GLUTAMINASE 1 (GLS1) TARGETING IN NON-ALCOHOLIC STEATOHEPATITIS (NASH)	Jorge Simón	Received

FRI-508	Acute Liver Failure-Organ Failure (ALF-OF) score is better than King´s College Hospital criteria in predicting mortality in patients with non-paracetamol-related acute liver failure (ALF).	Francesco Figorilli	Received

SAT-508	Clinical Outcomes in biopsy-proven NAFLD Patients from the HEPAmet Spanish Registry.	Javier Ampuero	Received

FRI-509	Drug Induced Liver Injury - A study on the factors affecting severity and prognosis with special emphasis on metabolic syndrome	Sandeep Narayanan	Received

THU-509	Epigenetic modification ofurea cycle enzymes (UCE) in NAFLD animal models and patients:Implications for novel therapeutic approaches	Francesco De Chiara	Received

SAT-509	Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in Patienst with Advanced Fibrosis/Compensated Cirrhosis	Salvatore Petta	Received

THU-510	Ammonia:A novel target for the prevention of NAFLD progression in NASH	Francesco De Chiara	Received

FRI-510	Serum CXCL10, CXCL11, CXCL12 and CXCL14 chemokine patterns in patients with acute liver injury	Arnaud CHALIN	Received

SAT-510	A Comprehensive Assessment of Serial Transient elastography in various Liver disease Etiologies at the Toronto Liver Centre (CASTLE-TLC)	Kerstina Boctor	Received

SAT-511	Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients.	Amalia Gastaldelli	Received

FRI-511	The proportion of patients waitlisted for transplantation for HDS induced liver injury is increasing and differs by race	Joseph Odin	Received

THU-511	During aging osteopontin deficiency increases vulnerability to non-alcoholic fatty liver disease progression and the associated extrahepatic metabolic complications	Beatriz Gómez Santos	Received

THU-512	Discovery and validation of new modulators of necroptosis using phenotypic high throughput screening of a large compound library	Hugo Miguel de Sousa Brito	Received

FRI-512	Hepatic and renal tolerance of immune checkpoint inhibitors for cancer treatment: a retrospective monocentric cohort study	Lucia Parlati	Received

SAT-513	Saturated fat is more metabolically harmful for the human liver than polyunsaturated fat or simple sugars	Panu Luukkonen	Received

THU-513	Pharmacological inhibition of myeloperoxidase attenuates non-alcoholic steatohepatitis-induced liver fibrosis in mice	Anja Koop	Received

FRI-513	Impact of early corticosteroid treatment in patients with indeterminate acute severe hepatitis	Elisabeth Mohr	Received

SAT-514	Low-moderate alcohol use is associated with a lower prevalence of non-alcoholic fatty liver disease in Hispanics/Latinos living in the US: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)	Aynur Unalp-Arida	Received

FRI-514	Evaluation of the hepatoprotective effects of Polygonum Multiflorum Thunb in Acetaminophen induced liver injury	Amarzaya Chagnaadorj	Received

THU-514	Angiopoietin-like protein 8 is a novel vitamin D receptor-targeted lipogenic gene associated with non-alcoholic fatty liver	Carmelo García-Monzón	Received

THU-515	THE LIVER-SPECIFIC DELETION OF THE RESPIRATORY CHAIN INHIBITOR MCJ ATTENUATES NAFLD PROGRESSION BY ENHANCING HEPATIC BETA-OXIDATION	María Luz Martínez-Chantar	Received

SAT-515	Even modest alcohol use is associated with greater steatosis on magnetic resonance imaging in patients with NAFLD - a pilot study	Veeral Ajmera	Received

FRI-515	Prophylactic use of entecavir for lymphoma patients with past HBV infection: a randomized controlled trial	Wei Ping Liu	Received

SAT-516	Role of nutritional intake on clinical presentation of lean and overweight NAFLD	Rosa Lombardi	Received

THU-516	Targeting the NAFLD metabolome and the shaping of precision medicine for patients with NASH	Marta Iruarrizaga-Lejarreta	Received

FRI-516	Inhibition of pyruvate dehydrogenase complex and lactate dehydrogenase for therapy of acute liver failure	Rosa Ferriero	Received

FRI-517	Pyrrolizidine alkaloid-induced hepatic sinusoidal obstructive syndrome: clinical characteristics, imaging signs and pathological findings	Yuhu Song	Received

SAT-517	Non-alcoholic fatty liver disease is omega-6 fatty acids diet dipendent in a group of obese children	Anna Mantovani	Received

THU-517	The Pathophysiological Significance of Nerve Growth Factor in Non-alcoholic Fatty Liver Disease via FXR upregulation	MING-SHIAN TSAI	Received

THU-518	Modulation of the NLRP3 inflammasome pathway mediates the anti-inflammatory action of indoleamine dioxygenase in experimental NASH	Benedetta Piombanti	Received

FRI-518	Low Serum Hepcidin and High Transferrin Saturation are Associated with a Poor Short-term Survival in Adults with Acute Liver Failure	Igor Spivak	Received

THU-519	The role of dendritic cells in different stages of non-alcoholic fatty liver disease	Nahúm Méndez	Received

SAT-519	Change of microbiota in patients with improved fatty liver and obesity	Sang Bong Ahn	Received

FRI-519	43 candidate SNPs were not found to be associated with drug induced liver injury	Lili Pang	Received

SAT-520	Role of L-carnitine in pathogenesis of the atherogenic dyslipidemia in ischemic heart disease with concominent nonalcoholic steatohepatitis	Igor Skrypnyk	Received

THU-521	Partial hepatectomyand hemodynamics: insights fromnumerical modeling on vascular response	Dirk Drasdo	Received

SAT-521	Assessment of Baseline Hepatitis B Virus (HBV) Immunity and HBV Vaccine Responses in Prospectively Vaccinated Adults with Non Alcoholic Fatty Liver Disease (NAFLD)	Carla Coffin	Received

FRI-522	DRESS CASES INCLUDED IN THE SPANISH AND LATIN-AMERICAN DILI REGISTRIES: CLINICAL PHENOTYPE AND OUTCOME	Raul J. Andrade	Received

SAT-522	Clinical Characteristics and Epidemiology of Patients with Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in a Large Community-Based Healthcare Delivery System in the U.S.	Heather Patton	Received

FRI-523	Independent cohort validation of hepatic metabolism, daily dose and comorbidities as features associated with delayed symptom onset in drug-induced liver injury	Raul J. Andrade	Received

SAT-523	Sex hormone binding globulin levels are increased in HIV-infected men and are independently associated with lower odds of nonalcoholic fatty liver disease regardless of HIV serostatus	Daniel Zaldumbide	Received

FRI-524	Prediction of early mortality despite Liver Transplantation in Acute Liver Failure	Mariana Cardoso	Received

SAT-524	The Conundrum of Cryptogenic Liver Disease with Advanced Fibrosis: Poor Clinical Outcomes without Treatment Options	Zobair Younossi	Received

SAT-525	The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM)	Zobair Younossi	Received

FRI-525	Should age be an absolute contraindication to Liver Transplantation in Acute Liver Failure?	Mariana Cardoso	Received

SAT-526	Moderate Alcohol Consumption Protects Against Fatty Liver in Males	Takemi Akahane	Received

PSO-527	Handouts	Daniel Zaldumbide	Received

FRI-895	Poster Test	Patricia Pochelon	Received

The International Liver Congress 2018

11-15 April 2018 Paris

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 20/10/2018 TO 21/04/2018

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.ILC2018.2018



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access